A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 1418
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PDE5
Long Form : phosphodiesterase type 5
No. Year Title Co-occurring Abbreviation
1996 Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization. ANP, DMPPO, SHR, SNP
1998 4-Benzylamino-1-chloro-6-substituted phthalazines: synthesis and inhibitory activity toward phosphodiesterase 5. ---
1998 Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. ANP
1998 Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. EFS, HCC, NO
1999 A new era in the treatment of erectile dysfunction. ED
1999 Effects of sildenafil citrate on human hemodynamics. cGMP, NO
1999 Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. IIEF
1999 Overall cardiovascular profile of sildenafil citrate. cGMP, NO
1999 Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. cGMP, NO
10  1999 Sildenafil (Viagra) and ophthalmology. ---
11  1999 Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. cGMP, NO
12  1999 Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. cAMP, cGMP
13  1999 [Pharmacological profiles of sildenafil (VIAGRA) in the treatment of erectile dysfunction: efficacy and drug interaction with nitrate]. NO
14  2000 4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5. ---
15  2000 Cardiovascular risk and sildenafil. ED, MI
16  2000 Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. cAMP, cGMP
17  2000 Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. cGMP, i.p, NO
18  2000 Evaluation of erectile response by continuous measurement of penile diameter in rats. cGMP, L-NAME, NO
19  2000 Inhibition of neuroeffector transmission in human vas deferens by sildenafil. NO, SNP
20  2000 Ocular safety of Viagra, (sildenafil citrate). ---
21  2000 Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. NO
22  2001 A conscious-rabbit model to study vardenafil hydrochloride and other agents that influence penile erection. i.v, NO, SNP
23  2001 Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. ---
24  2001 Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. ---
25  2001 Functional coupling between nitric oxide synthesis and VIP release within enteric nerve terminals of the rat: involvement of protein kinase G and phosphodiesterase 5. NO, PKG, VIP
26  2001 Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. NO
27  2001 N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. MED
28  2001 Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives. ---
29  2001 Phosphodiesterase 5 inhibition: effects on the coronary vasculature. ED
30  2001 Physiological significance of nitrergic transmission in human penile erection. CC, NO
31  2001 Relaxation effect of nitric oxide-donor on diabetic penile smooth muscle in vitro. NO, SNAP
32  2001 Sex and the patient with cardiovascular risk factors: focus on sildenafil. cGMP, ED, MI
33  2001 sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. eNOS, sGC
34  2001 Sildenafil. ED
35  2001 Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring. ---
36  2002 8-Aryl xanthines potent inhibitors of phosphodiesterase 5. ---
37  2002 A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. cGMP
38  2002 A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. ---
39  2002 Acute and chronic effects of T-1032, a novel selective phosphodiesterase type 5 inhibitor, on monocrotaline-induced pulmonary hypertension in rats. MAP, MCT, RVSP
40  2002 Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. BAD, FMD
41  2002 Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure. ANP, CHF, ET-1, GFR
42  2002 Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation. CH, NO, sGC, VSM
43  2002 Effect of sildenafil citrate upon myocardial ischemia in patients with chronic stable angina in therapy with beta-blockers. ---
44  2002 IC351 (tadalafil, Cialis): update on clinical experience. ED
45  2002 Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. cGMP, NO, SPECT
46  2002 Molecular mechanisms of cardiostimulatory effects of sildenafil. IBMX
47  2002 Pharmacology of phosphodiesterase-5 inhibitors. AUC, tmax
48  2002 Phosphodiesterase 5 inhibitors: current status and potential applications. ---
49  2002 Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. cGMP, ED
50  2002 Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. ED
51  2002 Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. R domain
52  2002 Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. ---
53  2002 Sildenafil induces retinal vasodilatation in healthy subjects. RVA
54  2002 The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. CAD, ED, ETT, METs
55  2002 Tolerability and safety profile of sildenafil citrate (Viagra) in Latin American patient populations. cGMP, ED
56  2002 Vardenafil. ED, GAQ, IIEF
57  2002 Viagra (sildenafil citrate) and ophthalmology. ED
58  2002 [Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. PHT
59  2002 [The effects of sildenafil citrate on the isolated rat aorta: comparative in vitro study]. ---
60  2003 A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. ED
61  2003 Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. RV
62  2003 Cardiovascular safety of PDE5 inhibitors. ED
63  2003 DA-8159, a new PDE5 Iihibitor, induces penile erection in conscious and acute spinal cord injured rabbits. ASCI, ICP, NO, SNP
64  2003 Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. NO
65  2003 Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. CHF, LV
66  2003 Effect of sildenafil (Viagra) on cerebral blood flow velocity: a pilot study. cGMP
67  2003 Efficacy of DA-8159, a new PDE5 inhibitor, for inducing penile erection in rabbits with acute spinal cord injury. ASCI
68  2003 Erectile dysfunction in the cardiac patient. ED
69  2003 Isolation of two isoforms of phosphodiesterase 5 from rat penis. ---
70  2003 Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. ---
71  2003 Non erectile dysfunction application of sildenafil. ---
72  2003 Novel PDE5 inhibitors for the treatment of male erectile dysfunction. ED
73  2003 Overview of phosphodiesterase 5 inhibition in erectile dysfunction. cGMP
74  2003 PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. ACh, FBF, SNP
75  2003 Pharmacology of phosphodiesterase 5 inhibitors. ---
76  2003 Phosphodiesterase type 5 (PDE5) inhibitors. ---
77  2003 Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. PAP
78  2003 Regulation of nitric oxide-sensitive guanylyl cyclase. GC, NO
79  2003 Sildenafil citrate does not affect cardiac contractility in human or dog heart. IBMX
80  2003 Sildenafil in erectile dysfunction: a critical review. ED
81  2003 Sildenafil, a phosphodiesterase-5 inhibitor, enhances the antinociceptive effect of morphine. NO
82  2003 Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. ED
83  2003 Tadalafil, a further innovation in the treatment of sexual dysfunction. ---
84  2003 Tadalafil: a new agent for erectile dysfunction. ---
85  2003 Therapeutic strategies for managing erectile dysfunction: a step-care approach. ---
86  2003 Time course of the interaction between tadalafil and nitrates. BP
87  2003 Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. CSMCs
88  2003 Vardenafil: a review of its use in erectile dysfunction. ED, GAQ, IIEF, SEP
89  2003 [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. ---
90  2003 [Advances in studies of Chinese herbs for improving relaxability of corporal smooth muscle]. ED
91  2003 [Medication of the month. Vardenafil (Levitra)]. ---
92  2004 Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil. hERG
93  2004 Allosteric sites of phosphodiesterase-5 sequester cyclic GMP. C-domain, R domain
94  2004 Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. CC
95  2004 Assessment of cardiovascular risk in patients with erectile dysfunction: focus on the diabetic patient. ED
96  2004 Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. ---
97  2004 cAMP modulates cGMP-mediated cerebral arteriolar relaxation in vivo. CVSMCs, MRP5, NO, ODN, SNAP
98  2004 Current concepts in the management of erectile dysfunction in men with prostate cancer. ED
99  2004 Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. NO, PAH
100  2004 Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. ---
101  2004 Emerging oral drugs for erectile dysfunction. ED
102  2004 Erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy: comparative phosphodiesterase-5 inhibitor efficacy for therapy and novel prevention strategies. ED
103  2004 Erectile dysfunction: evaluation and new treatment options. ED
104  2004 Hemodynamic effects of phosphodiesterase 5 and angiotensin-converting enzyme inhibition alone or in combination in conscious SHR. ---
105  2004 High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. PDE
106  2004 Influence of sildenafil on gastric sensorimotor function in humans. ---
107  2004 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. GFR, RBF
108  2004 Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. GC, NO
109  2004 Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway. ANP, HF, NPs
110  2004 Mechanisms of action of PDE5 inhibition in erectile dysfunction. cGMP
111  2004 Modulation of soluble guanylate cyclase activity by phosphorylation. GC, NO, SNP
112  2004 NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. ED, L-NAME, NO
113  2004 Nitric oxide inhibits arginine-vasotocin-induced increase of water osmotic permeability in frog urinary bladder. AVT, EHNA, nNOS, NO
114  2004 Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility. cGMP, ED, NO, NOS, PDE, sGC
115  2004 Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. ---
116  2004 Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. ICP, nNOS, NO
117  2004 Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. ED
118  2004 Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. NO
119  2004 Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. cGMP, ED, NO
120  2004 Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. cAMP, cGMP, CGRP
121  2004 Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. NO
122  2004 Restoration of couple's intimacy and relationship vital to reestablishing erectile function. ED
123  2004 Role of the cardiologist: clinical aspects of managing erectile dysfunction. CVD, ED, ER, PAH
124  2004 Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan. ED, GAQ, IIEF
125  2004 Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram. COX, HPLC, PDE4, PDE4A
126  2004 Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. LVCO, TEE, VTI
127  2004 Sildenafil: emerging cardiovascular indications. ---
128  2004 Spotlight on vardenafil in erectile dysfunction. ED, GAQ, IIEF, SEP
129  2004 Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. PKG
130  2004 The impact of sildenafil on molecular science and sexual health. ---
131  2004 Therapeutic options for patients returning to sexual activity. ED
132  2004 Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. ED, NO
133  2004 Tissue expression, distribution, and regulation of PDE5. cAMP, cGMP
134  2004 Treatment of erectile dysfunction. ED
135  2004 Update on oral treatments for male erectile dysfunction. ED
136  2004 Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. NO
137  2004 Vardenafil treatment for erectile dysfunction. ED
138  2004 Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction. ED
139  2004 Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). ---
140  2004 [Efficacy and safety of vardenafil for men with erectile dysfunction]. ED
141  2004 [Efficacy and safety of vardenafil in men with erectile dysfunction and depression]. ED
142  2004 [Pharmacodynamics and pharmacokinetics of vardenafil in patients with erectile dysfunction]. ---
143  2004 [Viagra, cialis, impase--which of them, to whom, when and how?]. ED
144  2005 A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? ED
145  2005 A review of controlled trials in the pharmacological treatment of premature ejaculation. GU
146  2005 Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. cGMP, GSK-3, SVZ
147  2005 An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. ED, IIEF, SEP
148  2005 Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. PASMCs
149  2005 Available and future treatments for erectile dysfunction. ED
150  2005 Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. ED, FMD, PLB, TAD
151  2005 Clinical monograph for drug formulary review: erectile dysfunction agents. ERD, PBM
152  2005 Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. IL-1beta, TNF-alpha
153  2005 Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. PE
154  2005 Drug treatment of pulmonary arterial hypertension: current and future agents. PAH
155  2005 Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. AO
156  2005 Effects of potassium channel inhibitors in the forced swimming test: possible involvement of L-arginine-nitric oxide-soluble guanylate cyclase pathway. FST, NO
157  2005 Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. NO, PPH
158  2005 Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. PH
159  2005 Erectile dysfunction and treatment of carcinoma of the prostate. ED
160  2005 Erectile dysfunction in patients with coronary artery disease. CAD, ED
161  2005 Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy. ED, IIEF, MUSE, VIP
162  2005 Erectile dysfunction: molecular biology, pathophysiology and pharmacological treatment. cGMP, ED, PDE5i
163  2005 Evaluating preference trials of oral phosphodiesterase 5 inhibitors for erectile dysfunction. ED, RCTs
164  2005 Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. CC, NO, VD
165  2005 Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. ---
166  2005 High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. ---
167  2005 Immunohistochemical localisation of PDE5 in Leydig and myoid cells of prepuberal and adult rat testis. ---
168  2005 Improving erectile function by silencing phosphodiesterase-5. cGMP, CSMCs, siRNA, SNP
169  2005 In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: no tachyphylaxis effect. ---
170  2005 In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit. ED, EFS, HC, SNP
171  2005 Management of erectile dysfunction by the primary care physician. ---
172  2005 Mechanism of tissue-selective drug action in the cardiovascular system. ---
173  2005 New achievement and novel therapeutic applications of PDE5 inhibithors in older males. ED
174  2005 NO-sensitive guanylyl cyclase and NO-induced feedback inhibition in cGMP signaling. GC, NO
175  2005 Past, present, and future: a 7-year update of Viagra (sildenafil citrate). ED
176  2005 Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. ED
177  2005 PDE-5 inhibitor, Vardenafil, increases circulating progenitor cells in humans. EPCs
178  2005 PDE-5 inhibitors: current status and future trends. ED
179  2005 Penile erectile responses to electric stimulation are enhanced by a new phosphodiesterase type-5 inhibitor. AUC, BP, ICP, ICP/BP
180  2005 Peripheral regulatory mechanisms in erection. cGMP, NO
181  2005 Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. ---
182  2005 Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. ---
183  2005 Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. ---
184  2005 Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. cGMP, ED, PDEs
185  2005 Phosphodiesterase 5 inhibitor, zaprinast, selectively increases cerebral blood flow in the ischemic penumbra in the rat brain. i.v, rCBF
186  2005 Phosphodiesterase 5 inhibitors for erectile dysfunction. ED
187  2005 Phosphodiesterase type 5 and high altitude pulmonary hypertension. HAPH, PAP
188  2005 Phosphodiesterase type 5 inhibitors: molecular pharmacology and interactions with other phosphodiesterases. ---
189  2005 Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. cGMP
190  2005 Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides. ---
191  2005 Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11. PDEs
192  2005 Recent insights into androgen action on the anatomical and physiological substrate of penile erection. ED
193  2005 Regulation of phosphodiesterase 5 expression and activity in human pregnant and non-pregnant myometrial cells by human chorionic gonadotropin. dbcAMP, hCG
194  2005 Relaxant effect of sildenafil in the rabbit basilar artery. NO
195  2005 Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. BN, ED
196  2005 Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. cGMP, DEA/NO, NO, SNP
197  2005 Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. CI, PAH, RV, SERAPH, WHO
198  2005 Simultaneous determination of synthetic phosphodiesterase-5 inhibitors found in a dietary supplement and pre-mixed bulk powders for dietary supplements using high-performance liquid chromatography with diode array detection and liquid chromatography-electrospray ionization tandem mass spectrometry. HPLC-DAD, HSA, MRM
199  2005 Stimulation of AQP2 membrane insertion in renal epithelial cells in vitro and in vivo by the cGMP phosphodiesterase inhibitor sildenafil citrate (Viagra). AQP2
200  2005 Testosterone and sexual activity. cGMP, NOS
201  2005 The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. ---
202  2005 The efficacy and safety of PDE5 inhibitors. ---
203  2005 The possible role of the NO-cGMP pathway in nociception: different spinal and supraspinal action of enzyme blockers on rat dorsal horn neurones. cGMP, NO
204  2005 The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. cGMP, NO
205  2005 Therapeutic approaches to pulmonary hypertension in hemoglobinopathies: Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathy. PH
206  2005 Tracking functions of cGMP-dependent protein kinases (cGK). cGK, VASP
207  2005 Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. ED, EF
208  2005 Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. ED, ICI, RP, SHIM
209  2005 [Advances in researches on the onset and duration of the action of sildenafil]. ED
210  2005 [Ageing men's sexual functions decline and the erectile dysfunction (ED) increase]. ADAM, ED
211  2005 [Effect of berberine on the mRNA expression of phosphodiesterase type 5 (PDE5) in rat corpus cavernosum]. Ber, RT-PCR
212  2005 [Emerging therapies for the treatment of pulmonary arterial hypertension]. ERAs
213  2005 [Erectile dysfunction after traumatic pelvic injury]. ---
214  2005 [Instructions for the combination of PDE5 inhibitors with alpha-blockers]. ---
215  2005 [Vardenafil: long-term and continuous treatment of severe erectile disorders]. ED
216  2006 A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. C-domain, cNPKs, R domain
217  2006 A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. NO
218  2006 A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability. ---
219  2006 Antidepressant-induced inhibition of genital vascular responses is reversed by vardenafil in female rabbits. GVR, NO, SNRI, SRI
220  2006 Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. ED, EF, IIEF, IPSS, LUTS, QoL
221  2006 Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. ED
222  2006 Characterization and functional role of androgen-dependent PDE5 activity in the bladder. SNP
223  2006 Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BPH, ED, EjD, LUTS
224  2006 Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidences. ED, PDE5is
225  2006 Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. ED, EF, GAQ, IIEF, ITT, SEP, TSS
226  2006 Comparison of phosphodiesterase type 5 (PDE5) inhibitors. ---
227  2006 Current and future pharmacotherapies of premature ejaculation. DPX, ED, PE, SSRIs, STI
228  2006 Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. SVZ
229  2006 Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. ED
230  2006 Dipyridamole may induce migraine in patients with migraine without aura. mca
231  2006 Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? ED
232  2006 Does testosterone have a role in erectile function? ED, SHBG
233  2006 Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. BCN, CT, ETB, PPED, SNP
234  2006 Effect of renal injury-induced neurogenic hypertension on NO synthase, caveolin-1, AKt, calmodulin and soluble guanylate cyclase expressions in the kidney. HTN, NO, sGC
235  2006 Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. cGMP, SNP
236  2006 Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. PD, TGF-beta1
237  2006 Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb. cGMP
238  2006 Efficacy of tadalafil in men with erectile dysfunction naive to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. EF, IIEF, IS, OS, SEP
239  2006 Emergency department considerations regarding erectile dysfunction. ACS, ED
240  2006 Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats. CNES, DOBE, ED, EDHF, NO
241  2006 Epimedium brevicornum Maxim extract relaxes rabbit corpus cavernosum through multitargets on nitric oxide/cyclic guanosine monophosphate signaling pathway. CC, cGMP, EbM, L-NAME, NO
242  2006 Erectile dysfunction and hypertension. BP, ED
243  2006 Erectile dysfunction in aging men: testosterone role in therapeutic protocols. EPC, NO
244  2006 Erectile dysfunction therapy in special populations and applications: coronary artery disease. ACS, CAD, ED
245  2006 Erectile potentials of a new phosphodiesterase type 5 inhibitor, DA-8159, in diet-induced obese rats. AUC, ED, ICP, ICP/BP, OP, OR
246  2006 Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. ED, EF, SEP2
247  2006 Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. HPV, NO, ROK
248  2006 Expression of myosin isoforms in the smooth muscle of human corpus cavernosum. CC, ED, MHC, MLC, SM
249  2006 Expression, distribution and regulation of phosphodiesterase 5. cAMP, cGMP, PKG
250  2006 Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. ---
251  2006 First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I. AEs, ED
252  2006 Gene therapy and erectile dysfunction: the current status. ED
253  2006 Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. CAD
254  2006 Immunohistochemical staining as a potential method for the identification of vaginal epithelial cells in forensic casework. CK, ERalpha
255  2006 Increased intracavernosal pressure response in hypertensive rats after chronic hemin treatment. ED, HO, ICP, SD, sGC, SHR
256  2006 Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. NO
257  2006 Inhibition of cGMP-phosphodiesterase-5 by biflavones of Ginkgo biloba. GBDF
258  2006 Inhibition of phosphodiesterase type 5 with tadalafil is associated to an improved activity of circulating angiogenic cells in men with cardiovascular risk factors and erectile dysfunction. CACs, ED, VRFs
259  2006 Inhibitors of phosphodiesterase 5 (PDE 5) inhibit the nerve-induced release of nitric oxide from the rabbit corpus cavernosum. cGMP, NO, sGC
260  2006 JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction. hERG
261  2006 Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. ---
262  2006 Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. BNP, PH, PVR, SVR
263  2006 Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. CI, ED, OR
264  2006 Microarray analysis of gene expression profile in the corpus cavernosum of hypercholesterolemic rats after chronic treatment with PDE5 inhibitor. ED
265  2006 Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. ---
266  2006 Nasal obstruction as a common side-effect of sildenafil citrate. cGMP, NO
267  2006 Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. FDA, NAION
268  2006 Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction. ---
269  2006 Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. cGMP, ED, NAION
270  2006 Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. ED
271  2006 Pathophysiology and treatment of diabetic erectile dysfunction. AGEs, cGMP, ED, NO, NOS
272  2006 Patients responding to phosphodiesterase type 5 inhibitor therapy: what do their sexual partners know? ED
273  2006 Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. ED
274  2006 Pharmacology of erectile dysfunction in man. ED
275  2006 Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6. ED, SAR
276  2006 Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. EFS, IR, NO, sem, sem
277  2006 Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. CHF, ED
278  2006 Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. ED
279  2006 Phosphodiesterase 5 mechanisms and therapeutic applications. cGMP, ED, NO
280  2006 Phosphodiesterase inhibitors in Raynaud's phenomenon. ---
281  2006 Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men. ED, IIEF, SCI
282  2006 Phosphodiesterase type 5 inhibithors in older males. ED, HPG
283  2006 Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction. ED
284  2006 Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells. cGMP, CSMC, NO, RT-PCR, SNAP, TAF
285  2006 Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. MDSCs
286  2006 Phosphodiesterase-5 inhibitors and their hemodynamic effects. ---
287  2006 Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. ---
288  2006 Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor. ED
289  2006 Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BOO, BPH, LUTS
290  2006 Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime. ---
291  2006 Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors. IPAH
292  2006 Relationship between vascular damage degrees and endothelial progenitor cells in patients with erectile dysfunction: effect of vardenafil administration and PDE5 expression in the bone marrow. ED, IMT, PCs
293  2006 Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. GAQ, ITT, LOCF, SEP
294  2006 Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction. ED, PAIRS
295  2006 Sexual experience of female partners of men with erectile dysfunction: the female experience of men's attitudes to life events and sexuality (FEMALES) study. ED, FEMALES, MALES
296  2006 Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. NTG
297  2006 Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin, hemeoxygenase and vascular endothelial growth factor. Ang-1, HCAEC, HO-1, Trx-1
298  2006 Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. cGMP, L-NAME, NO
299  2006 Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction. ED
300  2006 Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. BPH, ED, LUTS
301  2006 Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. ED, ES, nNOS, RT-PCR, SNP, STZ
302  2006 Testosterone therapy in erectile dysfunction and hypogonadism. ED
303  2006 Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reports. IIEF
304  2006 The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. ED, FDA, PDE5i
305  2006 The evolving role of testosterone in the treatment of erectile dysfunction. ED
306  2006 The management of phosphodiesterase-5 (PDE5) inhibitor failure. ED, NO
307  2006 The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. CAO, ED, IS
308  2006 The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. ---
309  2006 The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. ED
310  2006 Use of liquid chromatography-mass spectrometry and a hydrolytic technique for the detection and structure elucidation of a novel synthetic vardenafil designer drug added illegally to a "natural" herbal dietary supplement. ---
311  2006 Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification. ED, GAQ, IIEF
312  2006 Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction. ED
313  2006 Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners. ED, GAQ, LPCF, TSS
314  2006 Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. I/R, VAR
315  2006 [Erectile dysfunction, sexuality and sociocultural aspects]. ED
316  2006 [Phosphodiesterase inhibitors: effectiveness and new applications]. ---
317  2006 [Phosphodiesterase type 5 siRNA increases cGMP in the smooth muscle cells of human corpus cavernosum]. ED, siRNA
318  2006 [Reliable efficacy of vardenafil for treatment of erectile dysfunction]. ---
319  2006 [Whole rehabilitation: a new goal of erectile dysfunction therapy]. ED, eNOS, ICP
320  2007 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors. ---
321  2007 A case of long-term sildenafil therapy in a young dog with pulmonary hypertension. PH
322  2007 Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. BNP, cGMP, HF, NP, SIL
323  2007 Alterations in cGMP, soluble guanylate cyclase, phosphodiesterase 5, and B-type natriuretic peptide induced by chronic increased pulmonary blood flow in lambs. BNP, sGC
324  2007 Blockade of phosphodiesterase Type 5 enhances rat neurohypophysial excitability and electrically evoked oxytocin release. cGMP
325  2007 cDNA microarray analysis of differentially expressed genes in penile tissue after treatment with tadalafil. ED, IGFBP-6, NCS-1, NPR-1, PCR
326  2007 Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. COX-2, NO
327  2007 Centrally acting mechanisms for the treatment of male sexual dysfunction. ED
328  2007 Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. CN, CNR, CVOD, SMC
329  2007 Common approach to managing lower urinary tract symptoms and erectile dysfunction. 5ARIs, alpha-ARAs, ED, LUTS
330  2007 Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension. cGMP, CHD, PAH, PAP, PVR
331  2007 Computational Analysis of the Mechanism and Thermodynamics of Inhibition of Phosphodiesterase 5A by Synthetic Ligands. SSP
332  2007 Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. ---
333  2007 Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors. ---
334  2007 Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. cGMP, IBMX
335  2007 Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. CV, ED, NAION
336  2007 Cutaneous reaction to drugs used for erectile dysfunction: case report and review of the literature. ED
337  2007 Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. ---
338  2007 Design of second generation phosphodiesterase 5 inhibitors. HTS, MED
339  2007 Dynamic structures of phosphodiesterase-5 active site by combined molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations. MD, QM/MM
340  2007 Effect of chronic administration of sildenafil on sodium retention and on the hemodynamic complications associated with liver cirrhosis in the rat. ---
341  2007 Effects of L-arginine and phosphodiesterase-5 inhibitor, sildenafil, on inflammation and airway responsiveness of sensitized BP2 mice. BALF, cGMP, i.p, MCh, NO, WBP
342  2007 Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia. BPH, IUP
343  2007 Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity. AC, ART, GC, NO
344  2007 Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. ED
345  2007 Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association? NAION
346  2007 Erectile dysfunction, discrepancy between high prevalence and low utilization of treatment options: results from the 'Cottbus Survey' with 10 000 men. ED, IIEF, QoL
347  2007 Erectile dysfunction: does insulin resistance play a part? ED, NO
348  2007 Erectile dysfunction: monitoring response to treatment in clinical practice--recommendations of an international study panel. ED, EHS, IIEF
349  2007 Expression of messenger ribonucleic acid encoding for phosphodiesterase isoenzymes in human female genital tissues. FSD, mRNA, PCR
350  2007 Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. CDU, OA
351  2007 Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. ED
352  2007 FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. CN, GPx, ICP, NT, UNI
353  2007 Functional and morphological improvement in erectile tissue of hypertensive rats by long-term combined therapy with phosphodiesterase type 5 inhibitor and losartan. ARB, Col III, CSM, ED, eNOS, SHR, VSM, WKY
354  2007 Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. ED
355  2007 Glucose-6-phosphate dehydrogenase deficiency: an etiology for idiopathic priapism? G6PD, NO
356  2007 How urologists manage erectile dysfunction after radical prostatectomy: a national survey (REPAIR) by the French urological association. ED, ICIs, REPAIR, RP
357  2007 Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease. CAD, CFR, ED
358  2007 Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. BPH, cGMP, LUTS
359  2007 Interventions for sexual dysfunction following treatments for cancer. CI, ED, OR, RCTs, SD
360  2007 Intrafascial nerve-sparing endoscopic extraperitoneal radical prostatectomy. EERPE, nsEERPE
361  2007 Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats. ALI, NO
362  2007 Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms. ---
363  2007 Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. ED
364  2007 Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors. BMLR, CoMFA, CoMSIA, QSAR
365  2007 Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. ED, NO
366  2007 Optic atrophy after sildenafil use. NA-AION
367  2007 Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. ED, EDOS
368  2007 PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation. BW, LPD, PVR
369  2007 PDE5 inhibitors beyond erectile dysfunction. cGMP, ED
370  2007 PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. NOS, PAH, RV
371  2007 Phosphodiesterase type 5 inhibition coupled to strong reinforcement results in two periods of transient retention loss in the young chick. ---
372  2007 Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction. CVD, ED
373  2007 Phosphodiesterase type 5 inhibitors: state of the therapeutic class. ---
374  2007 Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. RV
375  2007 Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. ED
376  2007 Physiological regulation of penile arteries and veins. cAMP, CC, cGMP, ED, EDHF, eNOS, EP, IP, NO, NPY, PKC, PKG, RhoK, TKs
377  2007 Pregnancy-promoting actions of HCG in human myometrium and fetal membranes. hCG, HMGB1, iNOS
378  2007 Pulmonary hypertension: current diagnosis and treatment. ERAs, PAH, PH
379  2007 Recurrent venous thrombosis including cerebral venous sinus thrombosis in a patient taking sildenafil for erectile dysfunction. CVST, ED
380  2007 Relaxation of the isolated human internal anal sphincter by sildenafil. IAS, max, s.e.m
381  2007 Role of nitric oxide/cyclic GMP pathway in regulating spontaneous excitations in detrusor smooth muscle of the guinea-pig bladder. 8-Br-cGMP, cGMP, CPA, DSM, NO, SERCA, SNP
382  2007 Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. IPAH, NYHA, QoL, WHO
383  2007 Sildenafil citrate concentrations not affecting oxidative phosphorylation depress H2O2 generation by rat heart mitochondria. cGMP, mitoKATP, RCR, ROS, SOD
384  2007 Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling. PH, sGC
385  2007 Sildenafil reverses hypoxic pulmonary hypertension in highland and lowland newborn sheep. PAP
386  2007 Success of sildenafil treatment in neurogenic female sexual dysfunction caused by L5-S1 intervertebral disk rupture: a case report. ---
387  2007 Supervised scoring models with docked ligand conformations for structure-based virtual screening. AChE, ER, PPARgamma, SSM, TK
388  2007 Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. ED
389  2007 The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. BP, CRP, ED, EID, FMD, IIEF
390  2007 The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. AU, RP
391  2007 The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. CAMs, ECs, MAPK, PKG, sGC
392  2007 The role of statins in erectile dysfunction. ---
393  2007 Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. cGMP, NO, PAH
394  2007 Urinary and sexual manifestations of patients infected by HTLV-I. ATLL, HAM/TSP
395  2007 Use of liquid chromatography-mass spectrometry and a chemical cleavage reaction for the structure elucidation of a new sildenafil analogue detected as an adulterant in an herbal dietary supplement. ---
396  2007 Vardenafil restores erectile function to normal range in men with erectile dysfunction. ED, IIEF-EF
397  2007 Versatile effects of sildenafil: recent pharmacological applications. ---
398  2007 Which patients with sexual dysfunction are suitable for testosterone replacement therapy? cGMP, ED, LOH, NOS, PDE5i, SD, TDS
399  2007 [Androgen regulates penile erection at the peripheral level]. NOS
400  2007 [Novel indications for phosphodiesterase type 5 inhibitors]. cGMP, ED, PAH
401  2007 [Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction]. IIEFS
402  2007 [Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)]. NOIAN, SPC
403  2008 A double-blind, placebo-controlled, randomized clinical study of the effects of vardenafil on human nasal patency. MCAs, VAS
404  2008 A placebo-controlled study of sildenafil effects on cognition in schizophrenia. cGMP
405  2008 Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients. cGMP, NO
406  2008 An insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studies. ---
407  2008 Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. ED, FRC
408  2008 Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions. ACS, NO, PKG1beta, SNP
409  2008 Consensus scoring with feature selection for structure-based virtual screening. AChE, CS, FSCS, PPARgamma, RCS
410  2008 Contractile agonists attenuate cGMP levels by stimulating phosphorylation of cGMP-specific PDE5; an effect mediated by RhoA/PKC-dependent inhibition of protein phosphatase 1. PKC, PP1
411  2008 Desensitization of the soluble guanylyl cyclase/cGMP pathway by lipopolysaccharide in rat isolated pulmonary artery but not aorta. beta1, cGMP, ET-1, iNOS, LPS, NO, sGC, SNP
412  2008 Designer drugs in herbal aphrodisiacs. HPLC-DAD-MS, NMR
413  2008 Determination of a new type of phosphodiesterase-5 inhibitor, thioquinapiperifil, in a dietary supplement promoted for sexual enhancement. ---
414  2008 Effect of caffeine on erectile function via up-regulating cavernous cyclic guanosine monophosphate in diabetic rats. cGMP, ED, ICP
415  2008 Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. ED, IIEF-EF, NSRP, SEP
416  2008 Effect of sildenafil on middle-aged sexually active males with no erectile complaints: a randomized placebo-controlled double-blind study. ED, EDITS, EF, IIEF, QSL, SEAR
417  2008 Effect of vardenafil on endothelial progenitor cells in hypogonadotrophic hypogonadal patients: role of testosterone treatment. EPCs, HH, PCs
418  2008 Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model. BOO, BPH, EFS, LUTS
419  2008 Effects of phosphodiesterase inhibitors on the contractile responses of isolated human seminal vesicle tissue to adrenergic stimulation. EFS, PDE, SV
420  2008 Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. PTB, RV, SIL, TAPSE, VEC
421  2008 Effects of San-Huang-Xie-Xin-Tang on U46619-induced increase in pulmonary arterial blood pressure. COX-2, PASMCs, sGC, SHXT
422  2008 Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's disease. DA, MPTP, NSDA, TH
423  2008 Erectile dysfunction after external beam radiotherapy for prostate cancer. ED, EPIC, RT
424  2008 Erectile dysfunction and dyslipidemia: relevance and role of phosphodiesterase type-5 inhibitors and statins. ED
425  2008 Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective analysis. ---
426  2008 Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. ---
427  2008 Identification of benzamidenafil, a new class of phosphodiesterase-5 inhibitor, as an adulterant in a dietary supplement. HSA
428  2008 Impact of a long-term sildenafil treatment on pressor response in conscious rats with insulin resistance and hypertriglyceridemia. BP, FFRs
429  2008 Intravenous tezosentan and vardenafil attenuate acute hypoxic pulmonary hypertension. ---
430  2008 Long-term treatment of erectile dysfunction with a phosphodiesterase-5 inhibitor and dose optimization based on nocturnal penile tumescence. ED, EF, IIEF, NPTR, RigiScan
431  2008 Looking to the future for erectile dysfunction therapies. ED
432  2008 Mechanisms of the relaxant effect of vardenafil in rat penile arteries. NO
433  2008 Methyl (11aS)-1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo-[3',4':1,2]pyridin[3,4-b]indol-2-substituted acetates: synthesis and three-dimensional quantitative structure-activity relationship investigation as a class of novel vasodilators. MFA
434  2008 Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function. cGMP, VSMC
435  2008 Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. ED
436  2008 Oral phosphodiesterase type 5 inhibitors: nonerectogenic beneficial uses. cGMP
437  2008 PDE5 modulates oocyte spontaneous maturation via cGMP-cAMP but not cGMP-PKG signaling. COCs
438  2008 Persistent pulmonary hypertension in the newborn: therapeutic effect of sildenafil. ECMO, HP, NO, PPHN
439  2008 Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. CI
440  2008 Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. NO
441  2008 Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. cGMP, CN, PKG, SIL, TAC, WT
442  2008 Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. LUTS
443  2008 Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. cGMP, PAH
444  2008 Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. cGMP, FBF, NO
445  2008 Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1alpha signaling. HIF-1alpha, NO
446  2008 Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia. LUTS
447  2008 Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. ---
448  2008 Post-marketing surveillance of ischaemic optic neuropathy in male veterans co-prescribed phosphodiesterase-5 inhibitors with organic nitrates or alpha-blockers. ION, RR, VHA
449  2008 Prevention of nitroglycerin tolerance in vitro by T0156, a selective phosphodiesterase type 5 inhibitor. COX
450  2008 Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. ---
451  2008 Pulmonary embolism after tadalafil ingestion. PE
452  2008 Recreational use of PDE5 inhibitors by young healthy men: recognizing this issue among medical students. ED
453  2008 Sildenafil (Viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition. ATP, ERK, L-NAME, NO, ODQ, SNAP, TEA
454  2008 Sildenafil and phosphodiesterase-5 inhibitors for heart failure. cGMP, HF
455  2008 Sildenafil augments early protective transcriptional changes after ischemia in mouse myocardium. CMI, MI, SMI
456  2008 Sildenafil inhibits duodenal contractility via activation of the NO-K+ channel pathway. cGMP, NO
457  2008 Sildenafil: a review of its use in pulmonary arterial hypertension. PAH
458  2008 Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure. HF, HRR
459  2008 Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change. ---
460  2008 Structure -activity relationships of PDE5 inhibitors. ---
461  2008 Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. ISO, NOS, sGC, SIL
462  2008 Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension. ANP, cGMP, NEP, NO, PH
463  2008 Synthesis and pharmacological evaluations of sildenafil analogues for treatment of erectile dysfunction. ---
464  2008 Testosterone and erectile dysfunction. ---
465  2008 The effect of erectile function on the use of phosphodiesterase-5 inhibitors after radical prostatectomy in Japanese and U.S. men. ---
466  2008 The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. ED, EDITS, EF, GAQ, LOCF, PCP
467  2008 The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model. cGMP, L-NAME
468  2008 The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. ED, EF, GAQ, GAQ, IIEF
469  2008 The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP. BRET
470  2008 The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. BPH, cGK, LUTS, NO, sGC
471  2008 The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury. CC, NO, SCI, SNP
472  2008 The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease. ED
473  2008 The relationship between hypogonadism and erectile dysfunction. ED
474  2008 The role of PDE5 inhibitors in heme oxygenase-cGMP relationship in rat cavernous tissues. cGMP, CO, HO, NO
475  2008 Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BOO, BPE, LUTS
476  2008 Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. ---
477  2008 [Tadalafil for erectile dysfunction: outstanding efficacy for 36 hours]. ED
478  2008 [The basics of phosphodiesterase type 5 (PDE5) inhibition in urology]. PDE
479  2009 A chemical proteomics based enrichment technique targeting the interactome of the PDE5 inhibitor PF-4540124. ---
480  2009 Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. ETB, hBCs, SHR, VEGF, WKY
481  2009 Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme. ---
482  2009 Aspects of sexual satisfaction in men with erectile dysfunction: a factor analytic and logistic regression approach. ED, EDITS, IIEF, PCA, SEP
483  2009 Cardiovascular effects of phosphodiesterase type 5 inhibitors. cGMP, ED
484  2009 Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. ACh, BCN, ED, eNOS, nNOS, qRT-PCR, RRP, SNP, TAD
485  2009 Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. BPH, cGMP, LUT, NO, sGC, SMCs, SNP
486  2009 Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. ---
487  2009 Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats. BOO, EFS
488  2009 Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion. ---
489  2009 Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. BPH, CRCs, ED, EFS, LUTS
490  2009 Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan. ETRA, IPAH
491  2009 Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. ---
492  2009 Computational screening and design of traditional Chinese medicine (TCM) to block phosphodiesterase-5. MLR, SCs, TCM
493  2009 Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. ---
494  2009 Effect of Tadalafil on prostate haemodynamics: preliminary evaluation with contrast-enhanced US. AUC, BPH, CEUS, ROI, SI, TTP
495  2009 Effects of sildenafil on maternal hemodynamics and fetal growth in normal rat pregnancy. ---
496  2009 Effects of the PDE5-inhibitor vardenafil in a mouse stroke model. ---
497  2009 Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. AB, ED, IIEF-EF, IPSS, LUTS
498  2009 Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. ET, MCT, PAH, PVR, RV
499  2009 Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions. ED
500  2009 Erectile dysfunction following prostatectomy: prevention and treatment. ED, RP
501  2009 Erectile dysfunction in diabetes mellitus. ED
502  2009 Evaluation of therapeutic response of patients with erectile dysfunction. ---
503  2009 Evaluation of vardenafil for the treatment of subjective tinnitus: a controlled pilot study. SF-36, TQ
504  2009 Experimental models of Peyronie's disease. Implications for new therapies. PD, TGF-beta1
505  2009 Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation. ED
506  2009 Five-year experience with tadalafil in the UK: an effective treatment for erectile dysfunction. ED
507  2009 Follicle development and luteal cell morphology altered by phosphodiesterase-5 inhibitor. ---
508  2009 Gender differences in tail-skin flushing induced by nitrates and phosphodiesterase type 5 inhibitors in a climacteric mouse model. ---
509  2009 Ginsenoside Rg1 improves male copulatory behavior via nitric oxide/cyclic guanosine monophosphate pathway. cGMP, NO, SNP
510  2009 Glutaraldehyde-polymerized bovine hemoglobin and phosphodiesterase-5 inhibition. HBOC
511  2009 Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. ---
512  2009 Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. AEs, ED, SEP-3
513  2009 Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. CC, cNOS, DM, ED, eNOS, ICP/MAP, nNOS, RT
514  2009 Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells. PASMCs, RhoA, ROCK
515  2009 Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells. NFAT, PAH, PASMC, TRP
516  2009 Is penile length a factor in treatment of erectile dysfunction with PDE-5 inhibitor? ED, IIEF-EF
517  2009 Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? BPH, ED, LUTS, PDE5is
518  2009 Isolated polyarteritis nodosa of the genitourinary tract presenting with severe erectile dysfunction: a case report with long-term follow-up. ED, PAN
519  2009 Isolation and structural elucidation of cyclopentynafil and N-octylnortadalafil found in a dietary supplement. CD, PDA
520  2009 Mechanisms of activity-dependent plasticity in cellular nitric oxide-cGMP signaling. NO
521  2009 Mechanisms of cognitive alterations in hyperammonemia and hepatic encephalopathy: therapeutical implications. HE
522  2009 Men's sexual health: evaluating the effectiveness of print- and PDA-based CME. CME, ED, PDA
523  2009 Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case. NAION
524  2009 Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. ED, RCTs
525  2009 PDE5 inhibitors for LUTS. ED, LUTS
526  2009 PDE5 inhibitors in non-urological conditions. cGMP, ED
527  2009 Pharmacological management of benign prostatic hypertrophy with phosphodiesterase-5 inhibitors. BPH, ED, LUTS, QoL
528  2009 Phosphatidylethanolamine-binding proteins, including RKIP, exhibit affinity for phosphodiesterase-5 inhibitors. PEBP2
529  2009 Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. ---
530  2009 Phosphodiesterase 5 inhibitors prevent 3,4-methylenedioxymethamphetamine-induced 5-HT deficits in the rat. eNOS, PKG
531  2009 Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes. beta-AR, Ca, sGC, WT
532  2009 Phosphodiesterase inhibitors and the eye. cGMP
533  2009 Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. ED
534  2009 Phosphodiesterase type 5 inhibitors: unmet needs. ED
535  2009 Phosphodiesterase type 5 regulation in the penile corpora cavernosa. cGMP
536  2009 Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. BPH, LUTS
537  2009 Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver. ---
538  2009 Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats. BUN, eNOS, IR
539  2009 Protective effects of tadalafil on experimental spinal cord injury in rats. cGMP, GSH-Px, MDA, NO, SCI, SOD
540  2009 Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. RGS2
541  2009 Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. ED
542  2009 Sickle cell trait and priapism: a case report and review of the literature. NO
543  2009 Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. l-NAME
544  2009 Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV. CAAs
545  2009 Structural complexity of the testis and PKG I / StAR interaction regulate the Leydig cell adaptive response to repeated immobilization stress. IMO, NO, StAR
546  2009 Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents. PDE11
547  2009 Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. ED
548  2009 Tadalafil in the treatment of erectile dysfunction. ED
549  2009 Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives. ED
550  2009 Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. ED, SCI
551  2009 Ten-year follow-up of sildenafil use in spinal cord-injured patients with erectile dysfunction. ED, SCI, SEP2 and 3
552  2009 Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine? AEs, ED
553  2009 The effects of sildenafil on the functional and structural changes of ileum induced by intestinal ischemia-reperfusion in rats. ---
554  2009 The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. EDVs, PSVs, RI
555  2009 The identification of (-)-trans-tadalafil, tadalafil, and sildenafil in counterfeit Cialis and the optical purity of tadalafil stereoisomers. NIRS
556  2009 Timing of dose relative to sexual intercourse attempt in previous sildenafil citrate users treated with tadalafil: a geographical comparison from a single arm, open-label study. ANZ, CEE/ME, LA
557  2009 Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. ED
558  2009 Transdifferentiation of rat fetal brain stem cells into penile smooth muscle cells. alpha-SMA, ED, FBSCs, MLC
559  2009 Vardenafil increases cell proliferation in the dentate gyrus through enhancement of serotonin expression in the rat dorsal raphe. BrdU, TPH
560  2009 Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. LV
561  2009 [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. ED, NO
562  2009 [Impact of rAd5-shRNA- PDE5A3 on cGMP in the smooth muscle cells of human corpus cavernosum]. cGMP, RNAi, siRNA
563  2009 [Tadalafil for erectile dysfunction: excellent safety and tolerance]. ED
564  2009 [Wardenafil in combined treatment of patients with chronic bacterial prostatitis]. CBP
565  2010 1-(2-(2,2,2-trifluoroethoxy)ethyl-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors. ---
566  2010 1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors. ---
567  2010 8-isoprostane F2alpha up-regulates the expression of type 5 phosphodiesterase in cavernosal vascular smooth muscle cells: inhibition with sildenafil, iloprost, nitric oxide and picotamide. CVSMCs, ED, NADPH, NO
568  2010 A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway. EPCs, HIF
569  2010 An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction. ED
570  2010 Angiogenesis therapy for the treatment of erectile dysfunction. ED, VEGF
571  2010 Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression. ---
572  2010 Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. BPH, cGMP
573  2010 Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor. DOX
574  2010 Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. ED
575  2010 Characterization of the L-arginine-NO-cGMP pathway in spontaneously hypertensive rat platelets: the effects of pregnancy. cGMP, eNOS, iNOS, NO, SHRs
576  2010 Chronic vasodilation produces plasma volume expansion and hemodilution in rats: consequences of decreased effective arterial blood volume. NIF, Posm, PV
577  2010 Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. DED, DN, GAQ, IIEF, SEP2
578  2010 Conformation changes, N-terminal involvement, and cGMP signal relay in the phosphodiesterase-5 GAF domain. ---
579  2010 Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5). SHR
580  2010 Development of an immunoassay for rapid screening of vardenafil and its potential analogues in herbal products based on a group specific monoclonal antibody. ED, icELISA, McAb
581  2010 Dipyridamole synergizes with nitric oxide to prolong inhibition of thrombin-induced platelet shape change. NO, PKA, VASP
582  2010 Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. ED, IIEF-EF
583  2010 Effect of udenafil on portal venous pressure and hepatic fibrosis in rats. A novel therapeutic option for portal hypertension. BDL, PVP
584  2010 Effect of vardenafil on cerebral vasospasm following experimental subarachnoid hemorrhage in rats. SAH, TAC
585  2010 Effects of sildenafil and tadalafil on ischemia/reperfusion injury in fetal rat brain. GSH-Px, I/R, MDA, SOD
586  2010 Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. ED, EF, GAQ, IIEF, LSC
587  2010 Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis. ED, LSC, MS, SEP2-3
588  2010 Erectile dysfunction - when tablets don't work. ED
589  2010 Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. CAD, CT, ED
590  2010 Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. ARO, PDE5i, qRT-PCR
591  2010 G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. GPR35
592  2010 Gene therapy as future treatment of erectile dysfunction. ED, NO
593  2010 Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to a nitric oxide donor in the pregnant rat. MAP, NO, Sild
594  2010 Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. CF
595  2010 Investigating the role of protein kinase-G in the antidepressant-like response of sildenafil in combination with muscarinic acetylcholine receptor antagonism. FST
596  2010 Key features for designing phosphodiesterase-5 inhibitors. cGMP, CoMFA, CoMSIA, TCM
597  2010 Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. DOX, MnSOD, PKG
598  2010 Medical management of lower urinary tract symptoms. BPH, LUTS
599  2010 Mitochondrial oxidant stress increases PDE5 activity in persistent pulmonary hypertension of the newborn. PAs, PASMCs, PPHN
600  2010 Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. PKG, Tg
601  2010 Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects. ED, IIEF-5, IPSS, LUTS
602  2010 Opposing regulation of human alveolar type II cell differentiation by nitric oxide and hyperoxia. iNO, sGC, TTF
603  2010 Oral therapy for erectile dysfunction. ---
604  2010 Oxidative stress regulates left ventricular PDE5 expression in the failing heart. CHF, SOD, TAC
605  2010 Penile involvement in Systemic Sclerosis: New Diagnostic and Therapeutic Aspects. ED, SSc
606  2010 Pharmacotherapy for erectile dysfunction. ---
607  2010 Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis. CIs, ERAs, PAH, RRs
608  2010 Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. ED, PDE5i
609  2010 Phosphodiesterase type 5 inhibitors for high-altitude pulmonary hypertension: a meta-analysis. HAPH
610  2010 Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. BTB, MBEC
611  2010 Phosphodiesterase-5 gene (PDE5A) polymorphisms are associated with progression of childhood IgA nephropathy. cGMP, IgAN, PDE5A, SNPs
612  2010 Phosphodiesterase-5 inhibitor tadalafil acts on endothelial progenitor cells by CXCR4 signalling. EPC
613  2010 Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. PAH
614  2010 Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. ---
615  2010 Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. DOX
616  2010 Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. 3-NP, HD
617  2010 Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. DMD
618  2010 SOD and inhaled nitric oxide normalize phosphodiesterase 5 expression and activity in neonatal lambs with persistent pulmonary hypertension. 1DSB, iNO, PPHN, ppm, rhSOD, sGC
619  2010 Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. cGMP
620  2010 Target profiling of a small library of phosphodiesterase 5 (PDE5) inhibitors using chemical proteomics. ITC, MS
621  2010 The effects of phosphodiesterase type 5 inhibitors on penile rigidity variables during a period with no sexual stimulation: a laboratory setting double-blind study. ED, PE
622  2010 The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. PAH, PH
623  2010 Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. BPH, ED, LUTS, NO
624  2010 Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP. AGE, cGMP, ED, HUVEC, MCP-1, NO, RAGE, RAGE, ROS, RT-PCR
625  2010 [Clinical use of phosphodiesterase-5 inhibitors in cardiopulmonary diseases: from experimental evidence to clinical application]. ---
626  2010 [Computational study on drug design and prediction of bioactivity for regulation of non-controlled psychotropic substances]. ---
627  2010 [Efficacy and safety of tadalafil for erectile dysfunction: an updated review]. ED
628  2010 [Regulation of cardiovascular functions by the phosphorylation of TRPC channels]. ---
629  2010 [Testosterone deficit syndrome and erectile dysfunction]. TDS
630  2010 [Vardenafil for refractory erectile dysfunction: the latest advances]. ED
631  2011 A Chinese herbal formula, Shuganyiyang capsule, improves erectile function in male rats by modulating Nos-CGMP mediators. cGMP, ED, NOS, SGYY
632  2011 A novel approach to simultaneous screening and confirmation of regulated pharmaceutical compounds in dietary supplements by LC/MS/MS with an information-dependent acquisition method. DSs, ED, IDA-EPI, MRM
633  2011 A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naive to PDE5 inhibitors. AEs, ED, EF, IIEF, SEP
634  2011 Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction. ---
635  2011 An overview of pharmacotherapy in premature ejaculation. ED, IELT, PE, SSRIs
636  2011 Antenatal sildenafil treatment attenuates pulmonary hypertension in experimental congenital diaphragmatic hernia. CDH, NO
637  2011 Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. WHO
638  2011 Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management. ED, LUTS
639  2011 Central nervous system agents and erectile dysfunction. ---
640  2011 Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study. 6MWD, EPBF, ES, PVR, SVR, WHO
641  2011 Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. CN, ED, ICP/MAP, RP, sGC
642  2011 Combining 2D and 3D in silico methods for rapid selection of potential PDE5 inhibitors from multimillion compounds' repositories: biological evaluation. ---
643  2011 Comparison of virtual high-throughput screening methods for the identification of phosphodiesterase-5 inhibitors. MMGBSA, NIB, vHTS
644  2011 Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding. ---
645  2011 Cyclic GMP signaling in rat urinary bladder, prostate, and epididymis: tissue-specific changes with aging and in response to Leydig cell depletion. cGMP, sGC
646  2011 Differential expression of PDE5 in failing and nonfailing human myocardium. RV
647  2011 Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models. Ao, cGKI, LV, PA, RV
648  2011 Differential vasoactive effects of sildenafil and tadalafil on cerebral arteries. ---
649  2011 Effect of a phosphodiesterase 5 inhibitor on pulmonary and cerebral arteries of newborn piglets with chronic hypoxia-induced pulmonary hypertension. MCA
650  2011 Effects of hydrogen sulfide on erectile function and its possible mechanism(s) of action. ED
651  2011 Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies. ED
652  2011 Erectile dysfunction and hypogonadism (low testosterone). ED
653  2011 Erectogenic Effects of Clerodendron capitatum: Involvement of Phosphodiesterase Type-5 Inhibition. CCSM, PNPPP
654  2011 Expression and distribution of key enzymes of the cyclic GMP signaling in the human clitoris: relation to phosphodiesterase type 5 (PDE5). cGKI, GMP, NO
655  2011 Hydrocortisone normalizes oxygenation and cGMP regulation in lambs with persistent pulmonary hypertension of the newborn. 1DSB, PPHN, ROS, sGC
656  2011 Immunohistochemical and functional characterization of nitric oxide signaling pathway in isolated aorta from Crotalus durissus terrificus. ACh, NO, sGC, SNP
657  2011 Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). BMSFI, ED, FT, TRiUS, TRT, TT
658  2011 Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors. ---
659  2011 Leber's hereditary optic neuropathy precipitated by tadalafil use for erectile dysfunction. LHON
660  2011 Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats. CO, HR, MAP, RVSP
661  2011 New insights into the pathophysiology of sickle cell disease-associated priapism. ---
662  2011 Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health. ED, NPs
663  2011 Outcomes of crural ligation surgery for isolated crural venous leak. CG, CLS, EF, EFD, ICI, ICVL, IIEF, PC
664  2011 Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. ACE, DCM, DMD, nNOS, TRPC
665  2011 PDE5 inhibitors: targeting erectile dysfunction in diabetics. CVD, ED
666  2011 Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not. ANP, NO, PDEs
667  2011 Phosphodiesterase 5 inhibition attenuates cerebral vasospasm and improves functional recovery after experimental subarachnoid hemorrhage. NO-cGMP, SAH
668  2011 Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. CPX, EOB, HF, PAP, PVR
669  2011 Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism? cGMP
670  2011 Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. ED
671  2011 Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. HF
672  2011 Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. CI
673  2011 Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. BDNF, cGMP, MBP, PKGI
674  2011 Preconditioning by phosphodiesterase-5 inhibition improves therapeutic efficacy of adipose-derived stem cells following myocardial infarction in mice. ASCs, bFGF, VEGF
675  2011 Prevalence and medical management of erectile dysfunction in Asia. ED, RCTs
676  2011 Pulmonary arterial hypertension and statins: an update. PAH
677  2011 Recurrent uveitis due to sildenafil usage in a patient with Behcet's disease. BD
678  2011 Sexual dysfunction, HIV, and AIDS in men who have sex with men. ED, IIEF, MSM, PEDT
679  2011 Sexual quality of life for localized prostate cancer: a cross-cultural study between Japanese and American men. QoL
680  2011 Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? CSC
681  2011 Sildenafil improves epicenter vascular perfusion but not hindlimb functional recovery after contusive spinal cord injury in mice. BMS, cGMP, CNS, NO, SCI
682  2011 Sildenafil inhibits calcineurin/NFATc2-mediated cyclin A expression in pulmonary artery smooth muscle cells. CDK2, PASMCs, PKG
683  2011 Sildenafil promotes smooth muscle preservation and ameliorates fibrosis through modulation of extracellular matrix and tissue growth factor gene expression after bilateral cavernosal nerve resection in the rat. BCNR, CTGF, EREG, PDGF, SIL, SM
684  2011 Sildenafil reduces insulin-resistance in human endothelial cells. HUVECs, NOS
685  2011 Sildenafil reduces polyuria in rats with lithium-induced NDI. AQP2, eNOS, Li, NDI, NHE3, NKCC2, SIL
686  2011 Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer's disease. Arc, BDNF, Cdk5, GSK-3beta
687  2011 Synthesis, Molecular Modeling, and Biological Evaluation of Novel Tetrahydro-beta-Carboline Hydantoin and Tetrahydro-beta-Carboline Thiohydantoin Derivatives as Phosphodiesterase 5 Inhibitors. ---
688  2011 Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. BPH, LUTS
689  2011 Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. FDA, PAH
690  2011 Testosterone replacement therapy in males with erectile dysfunction. ED, TRT
691  2011 The comparison of combination SSRI and PDE-5 inhibitor therapy to SSRI monotherapy in men with premature ejaculation. SSRI
692  2011 The effect of sildenafil on the elasticity of erythrocytes in homozygous sickle cell disease. cAMP, cGMP
693  2011 The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. ELT
694  2011 The management of erectile dysfunction: innovations and future perspectives. ED
695  2011 The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. MDR
696  2011 The promise of inhibition of smooth muscle tone as a treatment for erectile dysfunction: where are we now? ED
697  2011 The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. IIEF, ISS, PD
698  2011 Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors. ---
699  2011 Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors. ---
700  2011 Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings. CCSMCs, cGMP, eNOS, ICP, MAP, NO, STZ
701  2011 Vardenafil Enhances Oxytocin Expression in the Paraventricular Nucleus without Sexual Stimulation. PVN
702  2011 [ED patients and their female partners prefer tadalafil]. ED
703  2011 [Effects and mechanisms of phosphodiesterase type 5 inhibitors on rats with overactive bladder]. BC, cGMP, ICI, NVC, SHRs
704  2011 [Gene therapy for erectile dysfunction: an update]. ED
705  2011 [Psychosomatic treatment: a key to the improvement of erectile dysfunction]. ED
706  2011 [Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension]. ERS, ESC, PH
707  2011 [Update of PDE5 inhibitors for the treatment of ischemia-reperfusion]. ED
708  2012 A Phase I clinical trial of lodenafil carbonate, a new phosphodiesterase Type 5 (PDE5) inhibitor, in healthy male volunteers. AMAP
709  2012 A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design. AA2AR, GPCRs, S1PR1
710  2012 A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. CI, ED, OAD, PAIRS, PRN, SEAR
711  2012 A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction. ED, EF, IIEF
712  2012 Acute effects of sildenafil on uroflowmetric parameters in erectile dysfunction patients with and without lower urinary tract symptoms. ---
713  2012 Benign prostatic hyperplasia (BPH) management in the primary care setting. BPH, DRE, IPSS, PSA
714  2012 Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells. cGMP, FPASMC, NO, ROS
715  2012 Central serous chorioretinopathy due to tadalafil use. CSCR
716  2012 cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function. cGMP, NIHL
717  2012 Challenges in sexual medicine. ED
718  2012 Chronic inhibition of PPAR-gamma signaling induces endothelial dysfunction in the juvenile lamb. PBF, PKG-1alpha, PPARgamma, sGC
719  2012 Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. ED
720  2012 Chronic treatment with long acting phosphodiesterase-5 inhibitor tadalafil alters proteomic changes associated with cytoskeletal rearrangement and redox regulation in Type 2 diabetic hearts. GSKT-1, HSPA8, MLY
721  2012 Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction. IIEF, RRP
722  2012 Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5. cGMP
723  2012 Effect of novel synthetic evodiamine analogue on sexual behavior in male rats. ---
724  2012 Effect of vardenafil on semen parameters in infertile men: a pilot study evaluating short-term treatment. ED
725  2012 Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. ED, EFD, GAQ, IIEF, SEP
726  2012 Endothelial dysfunction enhances the pulmonary and systemic vasodilator effects of phosphodiesterase-5 inhibition in awake swine at rest and during treadmill exercise. cGMP, NO, PVR, SVR
727  2012 Evaluation of mechanism for antihypertensive action of Clerodendrum colebrookianum Walp., used by folklore healers in north-east India. ACE
728  2012 Examination of the effects of vardenafil on esophageal function using multichannel intraluminal impedance and manometry. MII-EM
729  2012 Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis. CoMFA, CoMSIA, MD
730  2012 Gouty arthritis at interphalangeal joint of foot after sildenafil use: A case report. ---
731  2012 Increased phosphodiesterase type 5 levels in a mouse model of type 2 diabetes mellitus. cGMP, DM, ED, HFD, ICPs, OS
732  2012 Influence of sildenafil on the anticonvulsant action of selected antiepileptic drugs against pentylenetetrazole-induced clonic seizures in mice. AEDs, CZP, ETS, PB, PTZ, TGB, VPA
733  2012 Inhibition of sympathetic neuroeffector transmission in human corpus cavernosum. ED, EFS, HCC, NO, sGC, SNP
734  2012 Intraurethral alprostadil for erectile dysfunction: a review of the literature. ED
735  2012 Irbesartan promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective long-term analysis. ARBs, EF, IIEF-5, RP, RRP, SPL
736  2012 Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. BPH, HFD, LUTS, MetS
737  2012 Mechanisms of action of botulinum neurotoxins, beta3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. DRG
738  2012 Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries. NO, SNP
739  2012 Oral tadalafil reduces intra-abdominal adhesion reformation in rats. ---
740  2012 Partial motor restoration upon administration of sildenafil: a case study. ---
741  2012 Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. NP
742  2012 PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis. CF
743  2012 PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. MRP7
744  2012 Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure. ACF, CHF, GFR, IAP, LAD, MI, RPF
745  2012 Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms. BBB, cGMP, ORT, PDE5is
746  2012 Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation. BPH, PrSC, Rho
747  2012 Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms. BPH, cGMP, ED, LUTS
748  2012 Pulmonary hypertension and right ventricular failure in left ventricular systolic dysfunction. LVSD, PVR, RVF
749  2012 Renoprotective effects of sildenafil in DOCA-salt hypertensive rats. ACR, DOCA, PCR, SBP, TGF-beta1
750  2012 Response to a single dose of sildenafil in single-ventricle patients: an echocardiographic evaluation. ---
751  2012 Role of phosphodiesterase-5 inhibitors in heart failure: emerging data and concepts. cGMP, HF
752  2012 Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes. cGMP, DN, NO, PDE-5, STZ, TGF
753  2012 Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. ED
754  2012 Separate or combined treatments with daily sildenafil, molsidomine, or muscle-derived stem cells prevent erectile dysfunction in a rat model of cavernosal nerve damage. ASMA, BCNR, CVOD, MDSC, nNOS, NO
755  2012 Sildenafil (Viagra) down regulates cytokines and prevents demyelination in a cuprizone-induced MS mouse model. MS
756  2012 Sildenafil enhances neurogenesis and oligodendrogenesis in ischemic brain of middle-aged mouse. APC, SVZ
757  2012 Sildenafil in Heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: rationale and design. HF, NYHA, PH, SilHF
758  2012 Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon. CVC, NO, RP
759  2012 Sildenafil influences the anticonvulsant activity of vigabatrin and gabapentin in the timed pentylenetetrazole infusion test in mice. AEDs, GBP, i.v, PTZ, VGB
760  2012 Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. DMD, MMP-13, NO-cGMP, TNF-alpha
761  2012 Sildenafil, a phosphodiesterase type 5 inhibitor, reduces antidepressant-like activity of paroxetine in the forced swim test in mice. ---
762  2012 Survival of Japanese patients with pulmonary arterial hypertension after the introduction of endothelin receptor antagonists and/or phosphodiesterase type-5 inhibitors. ERAs, PAH, PVR
763  2012 Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. ED
764  2012 Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. cGMP, ED, EFS, HBN, HIP, HPP, SNP
765  2012 The effects of PDE5 inhibitory drugs on renal ischemia/reperfusion injury in rats. eNOS, I/R, iNOS, MDA, MPO, RT-PCR
766  2012 The HelpED study: agreement and impact of the erection hardness score on sexual function and psychosocial outcomes in men with erectile dysfunction and their partners. ED, EHS, SEAR
767  2012 The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. cGMP
768  2012 Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5. CBF, cGMP, HIV-1, Tat-tg
769  2012 Transient rise of serum testosterone level after single sildenafil treatment of adult male rats. cAMP, cGMP, PRKG1, StAR, TIF
770  2012 Treatment for pulmonary hypertension of left heart disease. HF, pEF, PH
771  2012 Udenafil improves exercise capacity in patients with chronic obstructive pulmonary disease: a prospective study. 6MWD, 6MWT, COPD, PH, SGRQ
772  2012 Urologic medications and ophthalmologic side effects: a review. 5ARIs, IFIS, NAION
773  2012 [Erectile dysfunction and incontinence after prostatectomy. Treating the complications of surgery for prostate cancer]. ---
774  2012 [Hydrogen sulfide and penile erection]. CBS, CCSM, CO, CSE, ED, NO
775  2012 [Medical therapy of lower urinary tract symptoms [corrected]]. LUTS
776  2012 [New treatment strategies for male lower urinary tract symptoms]. LUTS
777  2013 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. EGCG
778  2013 A nationwide population study of trazodone use in urology patients. ED
779  2013 A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. ED, IIEF-EF
780  2013 A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of erectile dysfunction. ED, WTP
781  2013 A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex? ED, RCTs
782  2013 Adulteration of purported herbal and natural sexual performance enhancement dietary supplements with synthetic phosphodiesterase type 5 inhibitors. ED, OTC
783  2013 Alprostadil for the treatment of impotence. ED
784  2013 Application of high-performance liquid chromatography with charged aerosol detection for universal quantitation of undeclared phosphodiesterase-5 inhibitors in herbal dietary supplements. CAD, HPLC
785  2013 Assessing satisfaction in men and their female partners after treatment with phosphodiesterase type 5 inhibitors for erectile dysfunction. ED, EDITS
786  2013 Avanafil for erectile dysfunction. ED
787  2013 Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure. ER, TAC
788  2013 Correction of chloride transport and mislocalization of CFTR protein by vardenafil in the gastrointestinal tract of cystic fibrosis mice. CF, CFTR, GI
789  2013 Decreased permeability surface area for glucose in obese women with postprandial hyperglycemia: no effect of phosphodiesterase-5 (PDE-5) inhibition. ---
790  2013 Determination of sildenafil, vardenafil and aildenafil in human plasma by dispersive liquid-liquid microextraction-back extraction based on ionic liquid and high performance liquid chromatography-ultraviolet detection. AD, DLLME, IL, LODs, SD, VD
791  2013 Differential expression of multidrug resistance protein 5 and phosphodiesterase 5 and regulation of cGMP levels in phasic and tonic smooth muscle. MRP5
792  2013 Direct androgen regulation of PDE5 gene or the lack thereof. ARE, ED
793  2013 Distribution of phosphodiesterase type 5 (PDE5) in the lateral wall of the guinea pig urinary bladder. CGRP, NF, NO, PGP 9.5, SV2
794  2013 Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats. NO
795  2013 Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. CAD, cGMP, ED, FDA, NO
796  2013 Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study. ED, IIEF-5, K-MMSE, PHQ-15, PHQ-9
797  2013 Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. CGIC, ED, IELT, PE, PEP, TEAEs
798  2013 Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. AEs, IPSS, LUTS/BPH
799  2013 Evaluation of PET radioligands for in vivo visualization of phosphodiesterase 5 (PDE5). cGMP, PAH
800  2013 Familial hypercholesterolemia impairs exercise-induced systemic vasodilation due to reduced NO bioavailability. eNOS, FH, NLA, NO
801  2013 Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice. ---
802  2013 Geometry of the randomized evidence for treatments of pulmonary hypertension. ERA, PH
803  2013 Hyperspectral imaging of FRET-based cGMP probes. FRET, PKG
804  2013 Impact of phosphodiesterase type 5 inhibitor treatment on the rates of sexually transmitted diseases in a Veterans Affairs Medical Center patient population. STDs, VAMC
805  2013 Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling. AS, LV, TAC
806  2013 Increased PDE5 activity and decreased Rho kinase and PKC activities in colonic muscle from caveolin-1-/- mice impair the peristaltic reflex and propulsion. Cav-1, MLCP, NO
807  2013 Inhibition of calpain-regulated p35/cdk5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate. ---
808  2013 Modulation of paracetamol-induced hepatotoxicity by phosphodiesterase isozyme inhibition in rats: a preliminary study. NO-cGMP, PCM
809  2013 Monitoring by LC-MS/MS of 48 compounds of sildenafil, tadalafil, vardenafil and their analogues in illicit health food products in the Korean market advertised as enhancing male sexual performance. ---
810  2013 Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. EPIC, IIEF-EF, PPPR, RP
811  2013 Overactive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introduction. OAB, PG
812  2013 Packed red cell transfusions alter mesenteric arterial reactivity and nitric oxide pathway in preterm lambs. eNOS, NO, PRBC, sGC
813  2013 Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells. ---
814  2013 Phosphodiesterase 5 as target for adipose tissue disorders. NO, PKG
815  2013 Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions. BDNF, EAE, GrBs, MOG, MS
816  2013 Phosphodiesterase 5 inhibition-induced coronary vasodilation is reduced after myocardial infarction. MI, NO
817  2013 Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Chk2, gammaH2AX
818  2013 Phosphodiesterase inhibition facilitates cognitive restoration in rodent models of age-related memory decline. AD
819  2013 Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate. BPH, LUTS, nNOS, NO, VIP
820  2013 Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men. ANOVA, cGMP
821  2013 Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation. AEs, ED, IIEF
822  2013 Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons. ED
823  2013 Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. ---
824  2013 Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review. ---
825  2013 Phosphodiesterase-5 inhibition attenuates early renal ischemia-reperfusion-induced acute kidney injury: assessment by quantitative measurement of urinary NGAL and KIM-1. AKI, I/R
826  2013 Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. AD, cGMP, WT
827  2013 Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. I/R, NO, ROS
828  2013 Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. RCS, RCTs, RP
829  2013 Phosphodiesterases 3 and 5 express activity in the trigeminal ganglion and co-localize with calcitonin gene-related peptide. cAMP, cGMP, CGRP
830  2013 Protein kinase g ialpha inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. cGMP, LV, LZM, PKGIalpha, SIL, TAC
831  2013 Renal function in a rat model of neurogenic bladder, effect of statins and phosphodiesterase-5 inhibitors. ---
832  2013 Repeated and chronic administration of Vardenafil or Sildenafil differentially affects emotional and socio-sexual behavior in mice. PDEs
833  2013 Saw palmetto extract enhances erectile responses by inhibition of phosphodiesterase 5 activity and increase in inducible nitric oxide synthase messenger ribonucleic acid expression in rat and rabbit corpus cavernosum. iNOS, mRNA, SPE
834  2013 Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. ED
835  2013 Side effects reported by European consumers for medications for erectile dysfunction. ADR
836  2013 Sildenafil ameliorates biomarkers of genotoxicity in an experimental model of spontaneous atherosclerosis. DHE, MNC, ROS, WT
837  2013 Sildenafil and cardioprotection. ---
838  2013 Sildenafil attenuates placental ischemia-induced hypertension. RUPP, VEGF
839  2013 Sildenafil restores endothelial function in the apolipoprotein E knockout mouse. ACh, NO, ROS, WT
840  2013 SOP conservative (medical and mechanical) treatment of erectile dysfunction. ED, VIP
841  2013 Surgical treatment of Peyronie's disease by modified 16-dot placation in China. IIEF-5, PD
842  2013 Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3',5' monophosphate accumulation and adenosine 3'5' triphosphate release from human erythrocytes. ATP, cAMP, IPR, PAH, PDE3, TAD, ZAP
843  2013 Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. AD, CREB, PDE5is
844  2013 Tadalafil - a therapeutic option in the management of BPH-LUTS. BII, BPH, ED, IIEF, IPSS, LUTS, QoL
845  2013 Tadalafil for benign prostatic hyperplasia. BPH, ED
846  2013 Targeting nitric oxide in the subacute restorative treatment of ischemic stroke. cGMP, NO
847  2013 The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition. RV
848  2013 The efficacy and safety of on-demand Elonza; a generic product of sildenafil in Thai men with erectile dysfunction. ED, IIEF
849  2013 The GAy MEn Sex StudieS: erectile dysfunction among Belgian gay men. ED, EQS, GAMESSS, MSM, OR
850  2013 The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study. MD
851  2013 The role of cGMP in the physiological and molecular responses of the right ventricle to pressure overload. PAH, RV, RVH
852  2013 The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. ED, ICI
853  2013 Treatment Strategy for Non-Responders to PDE5 Inhibitors. ---
854  2013 ULTIMATE-SHF trial (UdenafiL Therapy to Improve symptoMAtology, exercise Tolerance and hEmodynamics in patients with chronic systolic heart failure): study protocol for a randomized, placebo-controlled, double-blind trial. SHF
855  2013 Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin. BAECs, cGMP, ED, IIEF-EFD, sGC
856  2013 Vascular regenerative therapies for the treatment of erectile dysfunction: current approaches. ED
857  2013 Vascular-targeted therapies for Duchenne muscular dystrophy. ACE, DMD, nNOS, NO, SC, VEGF
858  2013 [Calcineurin/NFAT signaling pathway mediates endothelin-1-induced pulmonary artery smooth muscle cell proliferation by regulating phosphodiesterase-5]. ET-1, PASMCs
859  2013 [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors]. cGMP, ED, LUTS
860  2013 [New application of phosphodiesterase-5 inhibitors in uro-andrology]. ---
861  2013 [PDE5 inhibitors for the management of temporary penile erectile dysfunction during treatment with assisted reproductive technology]. ART, ED, EHS
862  2013 [Profile of silodosin]. IPSS
863  2013 [Subarachnoid hemorrhage due to autonomic dysreflexia: rare consequence of sexual stimulation in a paraplegic]. AD
864  2014 Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. PH, RCTs, WMD
865  2014 An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naive to phosphodiesterase 5 inhibitor therapy. ED, EF, IIEF, SEP
866  2014 Analysis of illicit dietary supplements sold in the Italian market: identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. HRMS
867  2014 Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize eNOS expression in the fetal lamb model of congenital diaphragmatic hernia. CDH, PHTN
868  2014 Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. CI, NAION
869  2014 Avanafil for male erectile dysfunction: a systematic review and meta-analysis. AE, CI, ED, OR, RCTs
870  2014 Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor beta-induced Smad signaling. CBP1, CREB, TAC, TGF-beta1
871  2014 Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study. ED, KM, OaD
872  2014 Cross regulation between cGMP-dependent protein kinase and Akt in vasodilatation of porcine pulmonary artery. NO
873  2014 Decision tree analyses of key patient characteristics in Middle Eastern/North African and Latin American men treated with long-acting and short-acting PDE5 inhibitors for erectile dysfunction. LA, MENA
874  2014 Determination of phosphodiesterase-5 inhibitors and analogs using high-performance liquid chromatography with ultraviolet detection. APIs
875  2014 Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. ---
876  2014 Do randomized clinical trials with inadequate blinding report enhanced placebo effects for intervention groups and nocebo effects for placebo groups? IIEF-EF, RCTs
877  2014 Does phosphodiesterase inhibition lessen facial flap necrosis in tobacco cigarette users? ---
878  2014 Drug repurposing and the prior art patents of competitors. ---
879  2014 Effect of chronic Sildenafil treatment on the prostate of C57Bl/6 mice. ---
880  2014 Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy. BMD, MRI, nNOS
881  2014 Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension. PAH, PAP
882  2014 Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension. BP, LVDD, RHTN
883  2014 Effects of phosphodieastrase type 5 inhibitions on morphine withdrawal symptoms in mice. cGMP
884  2014 Erectile hydraulics: maximizing inflow while minimizing outflow. ED, NO
885  2014 Essential role of the cGMP/PKG signaling pathway in regulating the proliferation and survival of human renal carcinoma cells. cGMP, JNK, PKG
886  2014 Excess adenosine A2B receptor signaling contributes to priapism through HIF-1alpha mediated reduction of PDE5 gene expression. ADA, HIF-1alpha, SCD
887  2014 Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors. CPET, ED, IIEF
888  2014 Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. 6MWD, BNP, CI, HP, ILD, IPF, PAPm, PAWPM, PH, PVR
889  2014 Hydrocortisone normalizes phosphodiesterase-5 activity in pulmonary artery smooth muscle cells from lambs with persistent pulmonary hypertension of the newborn. cGMP, FPASMCs, NF-kappaB, PPHN
890  2014 Icariin, a phosphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling. AD, APP, cGMP, ICA, NO, NOS, SIL, WT
891  2014 Inhibition of phosphodiesterase 5 reduces bone mass by suppression of canonical Wnt signaling. cGMP, PKG, SFRP1
892  2014 Involvement of inducible nitric oxide synthase and dimethyl arginine dimethylaminohydrolase in Nomega-nitro-L-arginine methyl ester (L-NAME)-induced hypertension. DDAH, eNOS, IL-1beta, iNOS, L-NAME, MAP, NO, sGC
893  2014 Isolation and identification of novel propoxyphenyl thiosildenafil found in natural health food product. DAD, NMR, TOF/MS
894  2014 LC-ESI-MS/MS analysis of phosphodiesterase-5 inhibitors and their analogues in foods and dietary supplements in Korea. ---
895  2014 Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. ED
896  2014 Nitric-oxide inhibits nyctinastic closure through cGMP in Albizia lophantha leaflets. 8-Br-cGMP, cGMP, l-NAME, NO, sGC, SNAP, SNP
897  2014 PDE-5 inhibition improves skin flap viability in rats that are exposed to nicotine. i.p, s.c, VEGF
898  2014 PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. DMD
899  2014 PDE5 inhibitor efficacy is estrogen dependent in female heart disease. ---
900  2014 PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. I/R, PKG
901  2014 PDE5 inhibitors enhance celecoxib killing in multiple tumor types. ---
902  2014 PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. ---
903  2014 Phosphodiesterase 5 inhibition ameliorates angiontensin II-induced podocyte dysmotility via the protein kinase G-mediated downregulation of TRPC6 activity. TRPC6
904  2014 Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension. PAH
905  2014 Phosphodiesterase type 5 inhibition attenuates cyclosporine A induced nephrotoxicity in mice. cGMP, P-gp, PDGF-A, TGF-beta1
906  2014 Platelet-derived growth factor regulation of type-5 phosphodiesterase in human and rat penile smooth muscle cells. cAMP, cGMP, PDEs, PDGF, SMCs
907  2014 Powerful relaxation of phosphodiesterase type 4 inhibitor rolipram in the pig and human bladder neck. LUTS, NO, PHE, PKA
908  2014 Preservation of nitric oxide-induced relaxation of porcine coronary artery: roles of the dimers of soluble guanylyl cyclase, phosphodiesterase type 5, and cGMP-dependent protein kinase. sGC
909  2014 Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. AI, AI-tadalafil, BPH, cGMP, EFS, PE, SMA
910  2014 Pulmonary vasoconstrictor influence of endothelin in exercising swine depends critically on phosphodiesterase 5 activity. cGMP, ET, NO
911  2014 Radical perineal prostatectomy: Our initial experience. PSA, RPP
912  2014 Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor. BO, NO, PUO, sGC
913  2014 Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. GBM
914  2014 Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition. AMB, ERAs, PAH, PAP, RV, TAD
915  2014 Revisiting the slow force response: the role of the PKG signaling pathway in the normal and the ischemic heart. Lmax, NO, PKG, SFR
916  2014 Role of inorganic nitrate and nitrite in driving nitric oxide-cGMP-mediated inhibition of platelet aggregation in vitro and in vivo. eNOS, NO
917  2014 Role of the nitric oxide-soluble guanylyl cyclase pathway in obstructive airway diseases. cGMP, GTP, NO, sGC
918  2014 Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis. AII, cGKI, Ctr
919  2014 Selective depletion of vascular EC-SOD augments chronic hypoxic pulmonary hypertension. EC-SOD, GTPCH-1, PA, PH, SMC
920  2014 Severe pulmonary hypertension in adult pulmonary Langerhans cell histiocytosis: the effect of sildenafil as a bridge to lung transplantation. PH, PLCH
921  2014 Sex, drugs, and trial design: sex influences the heart and drug responses. PKG
922  2014 Sexual dysfunction in diabetes. ED
923  2014 Sildenafil citrate for prophylaxis of nephropathy in an animal model of contrast-induced acute kidney injury. CI-AKI, CM
924  2014 Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. DBMD, LVESV
925  2014 Sildenafil stimulates and dexamethasone inhibits pulmonary vascular development in congenital diaphragmatic hernia rat lungs. CDH
926  2014 Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5. cGMP, MAPK, NO, NSC
927  2014 Synthetic phosphodiesterase-5-inhibitors use/abuse and interest of hair testing: reporting of a rape case. ---
928  2014 Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. COPD
929  2014 Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia. ED, IPSS, LUTS/BPH
930  2014 Tadalafil prevents acute heart failure with reduced ejection fraction in mice. LV, MI
931  2014 Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. MDSC
932  2014 The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis. BPH, ED, IIEF-EF, IPSS, LUTS
933  2014 The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors. LUTS
934  2014 The role of regulatory proteins and S-nitrosylation of endothelial nitric oxide synthase in the human clitoris: implications for female sexual function. Cav-1, CNES, eNOS, Hsp90, NO, PI3K, sGC, SNO
935  2014 Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease. ---
936  2014 Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. HIF-1, PC
937  2014 Turning on cGMP-dependent pathways to treat cardiac dysfunctions: boom, bust, and beyond. cGKI, GCs, I/R
938  2014 Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. BDNF, NGF, nNOS, Nogo-R, TrkA, TrkB
939  2014 [Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction]. cGMP, NO
940  2014 [Treatment of erectile dysfunction after radical prostatectomy should be in accordance with standard regimens]. ---
941  2015 8-(3-chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors. ---
942  2015 A hypothesis on possible neurochemical mechanisms of action of cervical spinal cord stimulation in prevention and treatment of cerebral arterial vasospasm after aneurysmal subarachnoid hemorrhage. CBF, cGMP, NO, SAH, SCS
943  2015 A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model. AD, i.p, MWM, Sild, yonk
944  2015 Acute effect of sildenafil on inflammatory markers/mediators in patients with vasculogenic erectile dysfunction. ED, hs-CRP, hsIL-6, sVCAM-1, TNF-alpha
945  2015 Antinociceptive Effect of Vardenafil on Carrageenan-Induced Hyperalgesia in Rat: involvement of Nitric Oxide/Cyclic Guanosine Monophosphate/Calcium Channels Pathway. cGMP, NO
946  2015 Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension. ERA, HR, PAH, PHAROS, SSc, TTCW
947  2015 Characterization of TPN729 metabolites in humans using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. ---
948  2015 Cilostazol but not sildenafil prevents memory impairment after chronic cerebral hypoperfusion in middle-aged rats. CCH
949  2015 Clinical efficacy and safety of Vitaros/Virirec (Alprostadil cream) for the treatment of erectile dysfunction. AEs, ED
950  2015 Comparison of the effects of systemic sildenafil, tadalafil, and vardenafil treatments on skin flap survival in rats. ---
951  2015 Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease. AD, HDAC, HDACIs
952  2015 Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury. cGMP, CON, I/R, iNO, LV, MI, TAD, TnI
953  2015 Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. ---
954  2015 Current Diagnosis and Management of Erectile Dysfunction. ED
955  2015 Current use of phosphodiesterase inhibitors in urology. ED
956  2015 Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5. cGMP, ring-C
957  2015 Effect of a single treatment with tadalafil on blood flow in lower urinary tract tissues in rat models of bladder overdistension/emptying and abdominal aorta clamping/release. BBF, C/R, LUT, O/E, PBF
958  2015 Effect of PDE5 inhibition on the modulation of sympathetic alpha-adrenergic vasoconstriction in contracting skeletal muscle of young and older recreationally active humans. NO
959  2015 Effect of phosphodiesterase inhibitors in the bladder. ICs, LUTS
960  2015 Effects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral Calculosis. cGMP, NO
961  2015 Effects of phosphodiesterase-5 inhibitor on ischemic kidney injury during nephron sparing surgery: quantitative assessment by NGAL and KIM-1. AKI, NSS, SCr
962  2015 Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction. BOO, BOO-Tadalafil, Sham
963  2015 Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy. BNSRP, CI, ED, IIEF-EF, OR, SMD
964  2015 Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. ED, HbA1c
965  2015 Fetal and postnatal ovine mesenteric vascular reactivity. ADRA1A, eNOS, ET-1, MA, NE, NEC, sGC, SNAP
966  2015 Hydrogen Sulfide and Urogenital Tract. CBS, CSE
967  2015 In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity. CK-MB, CPK, DOX, GPx, LDH, NF-kappaB, PKA, ROS, SOD, TBARS
968  2015 Inhibition of type 5 phosphodiesterase counteracts beta2-adrenergic signalling in beating cardiomyocytes. PDEs
969  2015 Interventions to treat premature ejaculation: a systematic review short report. AEs, EMA, IELT, PE, RCTs, SSRIs
970  2015 Involvement of NO-cGMP pathway in anti-hyperalgesic effect of PDE5 inhibitor tadalafil in experimental hyperalgesia. cGMP, i.p, NO, p.o, PWLs, TAD
971  2015 Lobe-specific expression of phosphodiesterase 5 in rat prostate. DL, LL, VL
972  2015 Major depression induces oxidative stress and platelet hyperaggregability. MD, NO
973  2015 Male fertility following spinal cord injury: an update. EEJ, IUI, IVF/ICSI, PVS, SCI
974  2015 Management of Recurrent Ischemic Priapism 2014: A Complex Condition with Devastating Consequences. KTZ, RIP
975  2015 Mechanisms underlying spontaneous constrictions of postcapillary venules in the rat stomach. NO, PCVs
976  2015 Medical therapy for benign prostatic hyperplasia: a review. 5ARIs, BPH, OAB
977  2015 Natriuretic peptide resistance of mesenteric arteries in spontaneous hypertensive rat is alleviated by exercise. ANP, SHR
978  2015 New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon? NEP, VIP
979  2015 Nexavar/Stivarga and viagra interact to kill tumor cells. ---
980  2015 NF-kappaB Upregulates Type 5 Phosphodiesterase in N9 Microglial Cells: Inhibition by Sildenafil and Yonkenafil. cGMP, IL-1beta, iNOS, LPS, NF-kappaB, TNF-alpha
981  2015 Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. 5-HT2B, ACE, beta-AR
982  2015 Novel Therapeutic Targets for Phosphodiesterase 5 Inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis. ---
983  2015 OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies. ---
984  2015 Penile Rehabilitation Strategies Among Prostate Cancer Survivors. ED
985  2015 Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels. CSF, PET
986  2015 Phosphodiesterase inhibitory activity of the flavonoids and xanthones from Anaxagorea luzonensis. ---
987  2015 Phosphodiesterase type 5 inhibitors and kidney disease. CKD
988  2015 Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review. ED, LUTS/BPH
989  2015 Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. CI, NNT, RCTs
990  2015 Potentiation of cGMP signaling increases oxygen delivery and oxidative metabolism in contracting skeletal muscle of older but not young humans. cGMP
991  2015 Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes. cGMP, MA, NO, sGC
992  2015 Resveratrol and sildenafil synergistically improve diabetes-associated erectile dysfunction in streptozotocin-induced diabetic rats. cGMP, ED, eNOS, ICP, MAP, nNOS, STZ
993  2015 Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice. BPD, LV, PH, RA, RV, RVH
994  2015 S-nitrosylation of PDE5 increases its ubiquitin-proteasomal degradation. NO, NOS
995  2015 Selective Serotonin Reuptake Inhibitors Plus Phosphodiesterase-5 Inhibitors for Premature Ejaculation: A Systematic Review and Meta-analysis. AEs, CI, IELT, MD, PE, SSRIs
996  2015 Sexual Dysfunction Related to Drugs: a Critical Review. Part V: alpha-Blocker and 5-ARI Drugs. APSS, BPH, LUTS
997  2015 Sildenafil (Viagra) blocks inflammatory injury in LPS-induced mouse abortion: A potential prophylactic treatment against acute pregnancy loss? FGR, LPS, RPL
998  2015 Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents. ATP, cGMP
999  2015 Sildenafil Does Not Prevent Heart Hypertrophy and Fibrosis Induced by Cardiomyocyte Angiotensin II Type 1 Receptor Signaling. Ang II, AT1Rs, CMs, SIL
1000  2015 Sildenafil Increases the p50 and Shifts the Oxygen-Hemoglobin Dissociation Curve to the Right. cGMP
1001  2015 Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation. BM-SS, ICP, NOS, PDE5I, PKG, ROS, SCD, WT
1002  2015 Systematic Review of Phosphodiesterase-5 Inhibitor Use in Right Ventricular Failure Following Left Ventricular Assist Device Implantation. LVAD, RV
1003  2015 Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities. ED, EDATE, EDITS, IIEF
1004  2015 Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. HNSCC, MDSC
1005  2015 Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. IPSS
1006  2015 The emperor's new clothes: PDE5 and the heart. cGMP, HFpEF, PKG
1007  2015 The immediate effect of sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: a randomized control trial. CMR, HF, RV
1008  2015 The molecular targets of approved treatments for pulmonary arterial hypertension. PAH
1009  2015 Therapeutic effects of udenafil on pressure-overload cardiac hypertrophy. LV, SAC
1010  2015 Therapeutic options for hydrating airway mucus in cystic fibrosis. CF, CFTR, MCC, PCL
1011  2015 Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. ---
1012  2015 Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. ACE, AT1-RA, DU, ET1RA, PAH, RP, SSc
1013  2015 [Efficacy and safety of phosphodiesterase inhibitors for erectile dysfunction in diabetic men: A meta analysis]. ED, FEM, GAQ, IIEF-Q, REM, WMD
1014  2015 [Molecular biological studies of erectile dysfunction: an update]. ED
1015  2016 A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice. AD, CREB
1016  2016 Acute Sildenafil Use Reduces 24-Hour Blood Pressure Levels in Patients With Resistant Hypertension: A Placebo-Controlled, Crossover Trial. ABPM, RH
1017  2016 Alprostadil cream in the treatment of erectile dysfunction: clinical evidence and experience. AEs, ED
1018  2016 Angiotensin II-mediated hypertension impairs nitric oxide-induced NKCC2 inhibition in thick ascending limbs. Ang II, ET-1, NKCC2, NO, THALs
1019  2016 Avanafil for the treatment of erectile dysfunction. ED
1020  2016 Beneficial Effect of the Nitric Oxide Donor Compound 3-(1,3-Dioxoisoindolin-2-yl)Benzyl Nitrate on Dysregulated Phosphodiesterase 5, NADPH Oxidase, and Nitrosative Stress in the Sickle Cell Mouse Penis: Implication for Priapism Treatment. NO, SCD
1021  2016 BET 2: Tadalafil medical expulsive therapy in ureteral calculi: a new kid on the block? ---
1022  2016 Calcilytics enhance sildenafil-induced antiproliferation in idiopathic pulmonary arterial hypertension. CTEPH, IPAH, PASMCs
1023  2016 Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5). cGMP, PET
1024  2016 Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review. ED, EF
1025  2016 Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation. IELT, PE
1026  2016 Current therapies for premature ejaculation. PE, SSRIs
1027  2016 Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease. AD, CREB, HDAC, HDACs
1028  2016 Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain. cAMP, cGMP, PDEs
1029  2016 Dose-dependent effects of glucocorticoids on pulmonary vascular development in a murine model of hyperoxic lung injury. HC, MWT, PA, RVH
1030  2016 Drug Use on Mont Blanc: A Study Using Automated Urine Collection. ---
1031  2016 Effectiveness of Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction in Patients with Spinal Cord Trauma: Systematic Review and Meta-Analysis. SCI
1032  2016 Effects of an alpha1A/D-adrenoceptor antagonist, naftopidil, and a phosphodiesterase type 5 inhibitor, tadalafil, on urinary bladder remodeling in rats with spinal cord injury. SCI
1033  2016 Efficacy and safety of phosphodieterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis. ED, GEQ, SCI
1034  2016 Enantiomeric profiling of chiral drug biomarkers in wastewater with the usage of chiral liquid chromatography coupled with tandem mass spectrometry. PMA
1035  2016 Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. 5ARIs, BPH, LUTS
1036  2016 Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment. ADL, DU, RP, SSc, TFRs
1037  2016 Icariin Inhibits Pulmonary Hypertension Induced by Monocrotaline through Enhancement of NO/cGMP Signaling Pathway in Rats. cGMP, eNOS, ICA, L-NAME, NO, PH
1038  2016 Icariside II, a novel phosphodiesterase-5 inhibitor, attenuates streptozotocin-induced cognitive deficits in rats. AD, APP, BACE1, COX-2, ICS II, ICV-STZ, IL-1beta, NEP, TGF-beta1, TNF
1039  2016 Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease. AD, HDAC
1040  2016 l-Cys/CSE/H2S pathway modulates mouse uterus motility and sildenafil effect. CBS, CSE, l-Cys
1041  2016 Light-controlled relaxation of the rat penile corpus cavernosum using NOBL-1, a novel nitric oxide releaser. NO
1042  2016 Neuroprotective effects of sildenafil against oxidative stress and memory dysfunction in mice exposed to noise stress. NOR, RAM
1043  2016 PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease. ---
1044  2016 PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. ---
1045  2016 Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). GRs, LEs
1046  2016 Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation. KI, ROCK, WT
1047  2016 Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. CSC, PCSC, PKG
1048  2016 Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy. cGMP, DN
1049  2016 Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink. HRs
1050  2016 Phosphodiesterase-5 Inhibitor Use: An Under-Reported Cause ofProfuse Nasal Bleeding. cGMP
1051  2016 Potentiation of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans. cGMP, FBF, L-NMMA, NO
1052  2016 Protective effect of sildenafil on the genotoxicity and cytotoxicity in apolipoprotein E-deficient mice bone marrow cells. WT
1053  2016 Rapid determination of sildenafil and its analogues in dietary supplements using gas chromatography-triple quadrupole mass spectrometry. CI, EI, LLOQ, LOD
1054  2016 sGC-cGMP-PKG pathway stimulation protects the healthy but not the failing right ventricle of rats against ischemia and reperfusion injury. RV
1055  2016 Sildenafil (Viagra()) prevents and restores LPS-induced inflammation in astrocytes. CNS, LPS
1056  2016 Sildenafil ameliorates left ventricular T-tubule remodeling in a pressure overload-induced murine heart failure model. LV, T-tubule, TAB
1057  2016 Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. ROS
1058  2016 Single-Laboratory Validation Study of a Method for Screening and Identification of Phosphodiesterase Type 5 Inhibitors in Dietary Ingredients and Supplements Using Liquid Chromatography/Quadrupole-Orbital Ion Trap Mass Spectrometry: First Action 2015.12. MS
1059  2016 Sympathetic Hyperactivity, Increased Tyrosine Hydroxylase and Exaggerated Corpus Cavernosum Relaxations Associated with Oxidative Stress Plays a Major Role in the Penis Dysfunction in Townes Sickle Cell Mouse. eNOS, nNOS
1060  2016 Systemic sclerosis: markers and targeted treatments. ECM, HSTC, IVIG, RP, SSc
1061  2016 Tadalafil Promotes the Recovery of Peripheral Neuropathy in Type II Diabetic Mice. NGF, PDGF-C
1062  2016 Tadalafil reduces airway hyperactivity and protects against lung and respiratory airways dysfunction in a rat model of silicosis. ECM, TGF-beta1, TNF-alpha
1063  2016 The Endothelium-Dependent Nitric Oxide-cGMP Pathway. NO, sGC
1064  2016 The Importance of L-Arginine:NO:cGMP Pathway in Tolerance to Flunitrazepam in Mice. 7-NI, FNZ, L-NAME, NOS
1065  2016 The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer. ---
1066  2016 The vasodilatory effect of sulfur dioxide via SGC/cGMP/PKG pathway in association with sulfhydryl-dependent dimerization. cGMP, DTT, HDX, PE, sGC
1067  2016 The Woman's Heart: Insights into New Potential Targeted Therapy. PDE5is
1068  2016 Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples. ED, IIEF
1069  2016 Viagra releases the brakes on melanoma growth. ---
1070  2017 Aberrant cGMP signaling persists during recovery in mice with oxygen-induced pulmonary hypertension. BPD, cGMP, MWT, PA, PH, sGC
1071  2017 Aging and sexual health: getting to the problem. ED
1072  2017 Apoptosis induction of poly-S-nitrosated human serum albumin in resistant solid tumor under hypoxia can be restored by phosphodiesterase 5 inhibition. NO, Poly-SNO-HSA
1073  2017 Assessment of the Role of NO-cGMP Pathway in Orthodontic Tooth Movement Using PDE5 Inhibitors: An Animal Study. cGMP, NO, OTM, PDL
1074  2017 Audiometry results and TEOAE and DPOAE amplitudes in men taking a phosphodiesterase type 5 inhibitor for erectile dysfunction. cGMP, DPOAEs, TEOAEs
1075  2017 Augmentation of cGMP/PKG pathway and colonic motility by hydrogen sulfide. cGMP, CSE, dl-PPG, H2S, NO, sGC
1076  2017 Beneficial Effects of Sildenafil on Tissue Perfusion and Inflammation in a Murine Model of Limb Ischemia and Atherosclerosis. sE-Selectin, sICAM-1, tPAI-1
1077  2017 Classical activation of macrophages and vardenafil. CF
1078  2017 Comparative Effects of Alkaloid Extracts from Aframomum melegueta (Alligator Pepper) and Aframomum danielli (Bastered Melegueta) on Enzymes Relevant to Erectile Dysfunction. ACE, AChE, AP, BM, ED, GC
1079  2017 Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species. SOD2
1080  2017 Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. ---
1081  2017 Daily use of phosphodiesterase type 5 inhibitors as prevention for recurrent priapism. ---
1082  2017 Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease. AChE, AD, BBB, CREB
1083  2017 Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. PAH
1084  2017 Effect of sildenafil citrate in testosterone induced benign prostate hyperplasia rat model. BPH
1085  2017 Exercise training improves blood flow to contracting skeletal muscle of older men via enhanced cGMP signaling. ---
1086  2017 Flavonoid glycosides isolated from Epimedium brevicornum and their estrogen biosynthesis-promoting effects. CREB, PDE3
1087  2017 Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease. AD, cGMP, CREB, PDE5is
1088  2017 In Silico Investigations of Chemical Constituents of Clerodendrum colebrookianum in the Anti-Hypertensive Drug Targets: ROCK, ACE, and PDE5. MD, ROCK
1089  2017 In vitro inhibition of phosphodiesterase-5 and arginase activities from rat penile tissue by two Nigerian herbs (Hunteria umbellata and Anogeissus leiocarpus). ED
1090  2017 Inhibition of Phosphodiesterase 5 and Increasing the Level of Cyclic Guanosine 3',5' Monophosphate by Hydroalcoholic Achillea wilhelmsii C. Koch Extract in Human Breast Cancer Cell Lines MCF-7 and MDA-Mb-468. cGMP
1091  2017 Inhibition of phosphodiesterase-5 suppresses calcineurin/NFAT- mediated TRPC6 expression in pulmonary artery smooth muscle cells. ET-1, PASMCs, TRPC6
1092  2017 Liposomal-delivery of phosphodiesterase 5 inhibitors augments UT-15C-stimulated ATP release from human erythrocytes. ATP, PAH
1093  2017 Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins. DOX, Tada
1094  2017 Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. PH
1095  2017 Modulation of some markers of erectile dysfunction and malonaldehyde levels in isolated rat penile tissue with unripe and ripe plantain peels: identification of the constituents of the plants using HPLC. ACE, AChE, ED, HPLC-DAD
1096  2017 News in erectile dysfunction ED
1097  2017 PDE 5 inhibitor improves insulin sensitivity by enhancing mitochondrial function in adipocytes. OCR, OXPHOS, PGC-1alpha
1098  2017 Phenanthrenes from Eulophia macrobulbon as Novel Phosphodiesterase-5 Inhibitors. ---
1099  2017 Phosphodiesterase type 5 and cancers: progress and challenges. cGMP
1100  2017 Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis. CI, OR
1101  2017 Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation. ED, ODT
1102  2017 Phosphodiesterase-5 inhibition preserves exercise-onset vasodilator kinetics when NOS activity is reduced. cGMP, FBF, MAP, NO
1103  2017 Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. MDSC
1104  2017 Phosphodiesterase-5 inhibitors and their analogues as adulterants of herbal and food products: analysis of the Malaysian market, 2014-16. LC-MS IT-TOF
1105  2017 Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis. 6MWD, CHF, CI, LVEF, mPAP, OR, PASP, PH, PVR, RCTs
1106  2017 Potential risk of developing herpes simplex encephalitis in patients treated with sildenafil following primary exposure to genital herpes. BBB, HSE, HSV
1107  2017 Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer. PDE4
1108  2017 Pulmonary Hypertension Therapy and a Systematic Review of Efficacy and Safety of PDE-5 Inhibitors. PH
1109  2017 Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction. MI, NO, PH
1110  2017 Recreational Use of Phosphodiesterase 5 Inhibitors and Its Associated Factors among Undergraduate Male Students in an Ethiopian University: A Cross-Sectional Study. aOR, CI
1111  2017 Research in pharmacotherapy for erectile dysfunction. ED
1112  2017 Role of the unfolded protein response in determining the fate of tumor cells and the promise of multi-targeted therapies. ER, UPR
1113  2017 Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice. AOM/DSS, cGMP, DSS
1114  2017 Sildenafil, a phosphodiesterase-5 inhibitor, offers protection against carbon tetrachloride-induced hepatotoxicity in rat. ALP, AST, CAT, cGMP, gamma-GT, GPx, GST, HDL, SOD, TP
1115  2017 Synthesis and invitro evaluation of new fluorinated quinoline derivatives with high affinity for PDE5: Towards the development of new PET neuroimaging probes. AD
1116  2017 Synthesis and Structure Revision of Dimeric Tadalafil Analogue Adulterants in Dietary Supplements. HATU
1117  2017 Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro. CTEPH, IPAH, PASMCs
1118  2017 Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. ---
1119  2017 The augmentation of BK channel activity by nitric oxide signaling in rat cerebral arteries involves co-localized regulatory elements. cGKI, NO, PLA, PP2A
1120  2017 The Bio-Psycho-Social Dimension in Women's Sexual Desire: 'Argumentum ad novitatem'. ---
1121  2017 The Effect of Oral Phosphodiesterase-5 Inhibitors on Sperm Parameters: A Meta-analysis and Systematic Review. CI
1122  2017 The link between vascular dysfunction, bladder ischemia, and aging bladder dysfunction. AR, DO, LUTS
1123  2017 The mechanism of attenuation of epithelial-mesenchymal transition by a phosphodiesterase 5 inhibitor via renal klotho expression. EMT, GMP, NO, PCNA
1124  2017 Udenafil, a Phosphodiesterase 5 Inhibitor, Reduces Body Weight in High-Fat-Fed Mice. HF, MYD88, NF-kappaB, NPY, POMC, TLR4
1125  2017 Upregulation of SERT and ADORA1 in broilers with acute right ventricular failure. ADORA1, PH, SERT
1126  2017 Vardenafil reduces macrophage pro-inflammatory overresponses in cystic fibrosis through PDE5- and CFTR-dependent mechanisms. CF, CFTR, NOS, TNF, WT
1127  2017 [Erectile dysfunction : Current diagnostics and treatment]. ---
1128  2018 3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats. cGMP, eNOS, ET-1, ICA, MCT, mPAP, NO, PAH, RVHI
1129  2018 A Rare Case of Severe Idiopathic Stuttering Priapism in a Young Healthy Man. ---
1130  2018 An immunohistochemical and ultrastructural analysis of the retina in tadalafil (Cialis) treated rats. ---
1131  2018 Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension. eNOS, iNOS, NO-cGMP
1132  2018 Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis. BCC, CIs, ORs
1133  2018 Beneficial Morphofunctional Changes Promoted by Sildenafil in Resistance Vessels in the Angiotensin II-Induced Hypertension Model. Ang II, NO, ROS
1134  2018 Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market. CV
1135  2018 Characterization and Stability of Amorphous Tadalafil and Four Crystalline Polymorphs. DSC, FT, PLM, SEM, Td, TD-AM, TGA, XRPD
1136  2018 Chronic pelvic pain and prostate inflammation in rat experimental autoimmune prostatitis: Effect of a single treatment with phosphodiesterase 5 inhibitors on chronic pelvic pain. EAP
1137  2018 Chronic phosphodiesterase type 5 inhibition has beneficial effects on subcutaneous adipose tissue plasticity in type 2 diabetic mice. AT, SAT, SVF, VAT
1138  2018 Cyclic-GMP-Elevating Agents Suppress Polyposis in ApcMin mice by Targeting the Preneoplastic Epithelium. GCC
1139  2018 Design and synthesis of novel annulated thienopyrimidines as phosphodiesterase 5 (PDE5) inhibitors. ---
1140  2018 Design, synthesis, biological evaluation and invivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease. AD, HDAC6
1141  2018 Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors. AD, CNS, CREB, HDAC
1142  2018 Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. EF, MRI, PAB, PAH, RV, RVF
1143  2018 Effects of aging and exercise training on leg hemodynamics and oxidative metabolism in the transition from rest to steady-state exercise: role of cGMP signaling. ---
1144  2018 Effects of sildenafil treatment on thermogenesis and glucose homeostasis in diet-induced obese mice. BAT, DIO, iWAT
1145  2018 Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis. ---
1146  2018 Eulophia macrobulbon extract relaxes rat isolated pulmonary artery and protects against monocrotaline-induced pulmonary arterial hypertension. EM, MCT, PA, PAH
1147  2018 Exploring the binding mechanisms of PDE5 with chromeno[2,3-c]pyrrol-9(2H)-one by theoretical approaches. cGMP, MD, PAH, QM/MM
1148  2018 Hepatic safety of ambrisentan alone and in combination with tadalafil: a post-hoc analysis of the AMBITION trial. ABS, BCT, ERA, PAH, TAD, TBILI
1149  2018 Hydroalcoholic Extract of Levisticum officinale Increases cGMP Signaling Pathway by Down-Regulating PDE5 Expression and Induction of Apoptosis in MCF-7 and MDA-MB-468 Breast Cancer Cell Lines LOHE
1150  2018 Hypoxia/Reoxygenation of Rat Renal Arteries Impairs Vasorelaxation via Modulation of Endothelium-Independent sGC/cGMP/PKG Signaling. COXs, NOS, NOX, sGC
1151  2018 Modulatory effect of some citrus (Citrus limon, Citrus reticulata, Citrus maxima) peels on monoamine oxidase, phosphodiesterase-5 and angiotensin-1 converting enzyme activities in rat heart homogenate. ACE, MAO
1152  2018 No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma. cGMP
1153  2018 Novel effect of sildenafil on hair growth. cGMP, ERK, hDPCs, hHFs, PDGF, VEGF
1154  2018 Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5). AChE, AD, BBB, CREB
1156  2018 PDE5 inhibition eliminates cancer stem cells via induction of PKA signaling. ALDH, CSCs
1157  2018 Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report. LDLT, mPAP, PPH
1158  2018 Pharmacodynamics of the agents used for the treatment of erectile dysfunction. ED
1159  2018 Phenolic-rich extracts of Eurycoma longifolia and Cylicodiscus gabunensis inhibit enzymes responsible for the development of erectile dysfunction and are antioxidants. ACE, CG, EL, HPLC-DAD
1160  2018 Phosphodiesterase (PDE5) inhibition assay for rapid detection of erectile dysfunction drugs and analogs in sexual enhancement products. ---
1161  2018 Phosphodiesterase type 5 in men with vasculogenic and post-radical prostatectomy erectile dysfunction: is there a molecular difference? ED, ROCK, RP
1162  2018 Phosphodiesterase type 5 inhibitor attenuates chronic ischemia-induced prostatic hyperplasia in a rat model. AHP, BPH, SRP, VP
1163  2018 Phosphodiesterase-5 inhibition potentiates cerebrovascular reactivity in chronic traumatic brain injury. CBF, CGI, CVR, NO, TBI, TCVI
1164  2018 Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity. Arg1, G-MDSC, MDSC, NK, ROS
1165  2018 Pituitary adenoma apoplexy associated with vardenafil intake. ---
1166  2018 Pulmonary arterial hypertension in a multi-ethnic Asian population: Characteristics, survival and mortality predictors from a 14-year follow-up study. FC, PAH, REVEAL, WHO
1167  2018 Pulmonary Arterial Pressure Management Based on Oral Medicine for Pediatric Living Donor Liver Transplant With Portopulmonary Hypertension. ERAs, LDLT, PAP, PH, POPH
1168  2018 Pulmonary microvascular remodeling in chronic thrombo-embolic pulmonary hypertension. CTEPH, ET-1, NO
1169  2018 Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching. HPV, NO, PA, sGC, TXA2
1170  2018 Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population-based cohort study. SNHL
1171  2018 Role of neuronal nitric oxide synthase (nNOS) in Duchenne and Becker muscular dystrophies - Still a possible treatment modality? cGMP, nNOS, NO
1172  2018 Sildenafil 25 mg ODT+ Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie's Disease: A Matched-Pair Comparison Analysis. CCH, PD, PDQ, SD 4.58
1173  2018 Sildenafil Transiently Delays Early Alveolar Healing of Tooth Extraction Sockets. cGMP
1174  2018 Sudden hearing loss after cialis (tadalafil) use: A unique case of cochlear hydrops. MRI, SSNHL
1175  2018 TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial. FGR
1176  2018 Tadalafil attenuates hypotonicity-induced Ca2+ influx via TRPV2 and TRPV4 in primary rat bladder urothelial cell cultures. TRPM7, TRPV2
1177  2018 Tadalafil: 15 years' journey in male erectile dysfunction and beyond. MED, PAH, PBH
1178  2018 The cGMP-Degrading Enzyme Phosphodiesterase-5 (PDE5) in Cerebral Small Arteries of Older People. ---
1179  2018 Transdermal water-in-oil nanocarriers of nitric oxide for triggering penile erection. ED, HLB, NEs, NO, W/O
1180  2018 Treatment Algorithms for Systemic Sclerosis According to Experts. ARBs, CCBs, IVCYC, MMF, MRSS, MTX, PAH, RP, SSc
1181  2018 Vardenafil inhibiting parasympathetic function of tracheal smooth muscle. ---
1182  2018 [Assessment of the erectile function and patients' perception of improvement in Spanish patients with erectile dysfunction]. ---
1183  2018 [Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction]. BPH, ED
1184  2019 A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction. ED, LOE
1185  2019 A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer's Disease. AD, fALFF
1186  2019 A Review of Current and Emerging Therapeutic Options for Erectile Dysfunction. ED
1187  2019 Alkaloid extracts from Bitter leaf (Vernonia amygdalina) and Black nightshade (Solanum nigrum) inhibit phosphodiesterase-5, arginase activities and oxidative stress in rats penile tissue. ---
1188  2019 At-line LC-QTOF-MS micro-fractionation of Derris scandens (Roxb.) Benth, coupled to radioassay for the early identification of PDE5A1 inhibitors. ESI, HPLC, LC-QTOF-MS
1189  2019 Avanafil Inhibits the Contractility of the Isolated Caprine Detrusor Muscle. ATP, BKCa, cGMP
1190  2019 Characterization of TPN171 metabolism in humans via ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. ---
1191  2019 Chronic administration of sildenafil improves endothelial function in spontaneously hypertensive rats by decreasing COX-2 expression and oxidative stress. ACh, COX-2, NO, PHE, SHR, Sild, SNP
1192  2019 Cinaciguat in combination with insulin induces a favorable effect on implant osseointegration in type 2 diabetic rats. cGMP, PKGII, sGC, T2DM
1193  2019 Clinical Outcomes and Treatment Options in Patients With Pulmonary Hypertension Who Received Pulmonary Hypertension-Specific Drugs - Single-Center Case Series. PH
1194  2019 Comparison of the Effects of Tadalafil and alpha1-Adrenoceptor Antagonists on Spontaneous Seminal Emission and Electrical Field Stimulation-Induced Seminal Vesicle Contraction in Rats. alpha1-AR, BPH, eNOS, nNOS, SSE
1195  2019 Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension. ERAs, NO, PAH
1196  2019 Data on the optimisation and validation of a liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to establish the presence of phosphodiesterase 5 (PDE5) inhibitors in instant coffee premixes. LC-HRMS, ME, RE
1197  2019 Determination of phosphodiesterase 5 (PDE5) inhibitors in instant coffee premixes using liquid chromatography-high-resolution mass spectrometry (LC-HRMS). ICPs, LC-HRMS, LOD, LOQ, ME, QuEChERS, RE
1198  2019 Differential impact of severe familial hypercholesterolemia on regional skeletal muscle and organ blood flows during exercise: Effects of PDE5 inhibition. FH
1199  2019 Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension. cGMP, PDE5A, PG, PH, QoL
1200  2019 Effect of p-coumaric acid on the erectogenic enzyme activities and non-protein thiol level in the penile tissue of normal and doxorubicin-induced oxidative stress male rat. ACE, AChE, AMPdase, b.wt, DOX, ED, pCA
1201  2019 Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4Weeks of Chronic Hypoxia. PH
1202  2019 Effects of PDE5 inhibition on dystrophic muscle following an acute bout of downhill running and endurance training. 31P-MRS, BOLD, MRI, nNOSmu
1203  2019 Effects of phosphodiesterase 5 inhibitor sildenafil on the respiratory parameters, inflammation and apoptosis in a saline lavage-induced model of acute lung injury. ALI, ALI, BAL, cGMP
1204  2019 Elucidation of Vasodilation Response and Structure Activity Relationships of N,N⁴-Disubstituted Quinazoline 2,4-Diamines in a Rat Pulmonary Artery Model. PAH, PE
1205  2019 Exogenous l-ARGININE does not stimulate production OF NO or cGMP within the rat corporal smooth muscle cells in culture. CSM, L-Arg, L-Cit, NO
1206  2019 Exploration of icariin analog structure space reveals key features driving potent inhibition of human phosphodiesterase-5. ---
1207  2019 HPLC phenolic fingerprinting, antioxidant and anti-phosphodiesterase-5 properties of Rauwolfia vomitoria extract. FRAP, HPLC
1208  2019 In vitro antioxidant and enzyme inhibitory properties of the n-butanol fraction of Senna podocarpa (Guill. and Perr.) leaf. ABTS, ACE, AChE, BChE
1209  2019 Inhibitory effects of sildenafil and tadalafil on inflammation, oxidative stress and nitrosative stress in animal model of bronchial asthma. BALF, i.p, IL-4, MDA, NOx, TNF-alpha
1210  2019 Intervening with the Nitric Oxide Pathway to Alleviate Pulmonary Hypertension in Pulmonary Vein Stenosis. eNOS, HP/HF, HP/LF, NO, PH, PVB, PVS
1211  2019 Interventions to Treat Erectile Dysfunction and Premature Ejaculation: An Overview of Systematic Reviews. ---
1212  2019 Mirabegron, A Selective beta3-Adrenoceptor Agonist Causes an Improvement in Erectile Dysfunction in Diabetic Rats. AR, CC, ED, ICP
1213  2019 Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach. ED
1214  2019 Ocimum gratissimum Linn. Leaves reduce the key enzymes activities relevant to erectile dysfunction in isolated penile and testicular tissues of rats. ACE, AChE, DPPH, ED, FRAP
1215  2019 Optimization of Extraction Technology of Majun Mupakhi Ela and its Effect on Hydrocortisone-induced Kidney Yang Deficiency in Mice. BBD, ED, MME, RSM
1216  2019 Orange peels modulate antioxidant markers and key enzymes relevant to erection in the penile tissue of paroxetine-treated rats. AChE, ADA, ED, NO
1217  2019 P66Shc Deletion Ameliorates Oxidative Stress and Cardiac Dysfunction in Pressure Overload-Induced Heart Failure. SOD, TAC
1218  2019 PDE5A Suppresses Proteasome Activity Leading to Insulin Resistance in C2C12 Myotubes. 2-DG, ER
1219  2019 Penile calciphyilaxis treated with daily Tadalafil: Case report. ESRD
1220  2019 Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. PAH
1221  2019 Pharmacological and transcriptomic characterization of the nitric oxide pathway in aortic rings isolated from the tortoise Chelonoidis carbonaria. CCR, NO
1222  2019 Phenolic analysis and erectogenic function of African Walnut (Tetracarpidium conophorum) seeds: The impact of the seed shell on biological activity. ACE, AChE, AWS, ED, MDA
1223  2019 Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression. CAFs, MEFs, PDE
1224  2019 Phosphodiesterase 5 Associates With beta2 Adrenergic Receptor to Modulate Cardiac Function in Type 2 Diabetic Hearts. beta-AR, beta2AR, EC, HFD
1225  2019 Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease. AD
1226  2019 Phosphodiesterase 5 inhibitors for pulmonary hypertension. CI, CTEPH, ERAs, OR, PAH, PH, PH-LHD, PH-LHD, WHO
1227  2019 Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems. CRPC, HR, NHEJ
1228  2019 Phosphodiesterase-5 (PDE-5) Inhibitors and Ototoxicity: A Systematic Review. ---
1229  2019 Positive outcomes of phosphodiesterase type 5 inhibitor on histopathologic and biochemical changes induced by ureteral obstruction. alpha-SMA, TGF-beta, UUO
1230  2019 Potential for Long-Term Benefit of Cognitive Behavioral Therapy as an Adjunct Treatment for Men with Erectile Dysfunction. CBT, ED, PDE5i
1231  2019 Pro-cognitive effect of upregulating cyclic guanosine monophosphate signalling during memory acquisition or early consolidation is mediated by increased AMPA receptor trafficking. AMPAR, cAMP, cGMP
1232  2019 Protective effects of icariin on dorsal random skin flap survival: An experimental study. ICA, IL-6, MDA, SOD, VEGF
1233  2019 Pulmonary hypertension secondary to respiratory disease and/or hypoxia in dogs: Clinical features, diagnostic testing and survival. PH, sPAP
1234  2019 RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity. ---
1235  2019 Robotic radical prostatectomy in 93 cases: Outcomes of the first ERUS robotic urology curriculum trained surgeon in Turkey. ED, ERUS, LN, MAB, NVB, RARP, SM
1236  2019 Safety and Efficacy of Ambrisentan-Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice. ADR, PAH
1237  2019 Safety Evaluation of Tadalafil Treatment for Fetuses with Early-Onset Growth Restriction (TADAFER): Results from the Phase II Trial. FGR, TADAFER
1238  2019 Sildenafil citrate long-term treatment effects on cardiovascular reactivity in a SHR experimental model of metabolic syndrome. CD, cGMP, SHR
1239  2019 Sildenafil for Pulmonary Arterial Hypertension. FDA, NO, PAH
1240  2019 Sildenafil improves exercise capacity in patients with cystic fibrosis: a proof-of-concept clinical trial. CF
1241  2019 Sildenafil's impact on male infertility: what has changed in 20 years? ED
1242  2019 Spondias mombim L. (Anacardiaceae): Chemical fingerprints, inhibitory activities, and molecular docking on key enzymes relevant to erectile dysfunction and Alzheimer's diseases. ACE, E-NTDase, MAO, SMEAF
1243  2019 Synaptic and memory dysfunction induced by tau oligomers is rescued by up-regulation of the nitric oxide cascade. CREB, LTP, NO
1244  2019 Systemic medications linked to an increased risk for skin malignancy. JAK
1245  2019 Tadalafil alleviates preeclampsia and fetal growth restriction in RUPP model of preeclampsia in mice. FGR, PE, RUPP
1246  2019 Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease. AD, HDACs, HSP70
1247  2019 Targeting cyclic nucleotide phosphodiesterase 5 (PDE5) in brain: Toward the development of a PET radioligand labeled with fluorine-18. PET
1248  2019 Testosterone and the Heart. CHF, CV, CVD, ED, T2D, TD
1249  2019 The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis. ---
1250  2019 Ultrastructural Study of Clitoral Cavernous Tissue and Clitoral Blood Flow From Type 1 Diabetic Premenopausal Women on Phosphodiesterase-5 Inhibitor. EDV, PI, PSV, SMCs
1251  2019 Use of Phosphodiesterase 5 Inhibitors Is Associated With Lower Risk of Colorectal Cancer in Men With Benign Colorectal Neoplasms. CIs, CRC, HRs
1252  2019 Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study. CCBs, DU, DUs, ERAs, OT1, SSc
1253  2019 Vascular Response to Sildenafil Citrate in Aging and Age-Related Macular Degeneration. AMD, EDI-OCT, OCTA
1254  2019 [LC/Tribrid Orbitrap Analysis of Phosphodiesterase-5 Inhibitors and Their Analogs as Adulterants in Dietary Supplements]. ---
1255  2020 A meta-analysis of efficacy and safety of PDE5 inhibitors in the treatment of ureteral stent-related symptoms. CI, MD, OR, RCTs
1256  2020 A new approach at diabetic foot treatment: Phosphodiesterase 5 inhibitors. DF, DM
1257  2020 A synthetic mimic of phosphodiesterase type 5 based on corona phase molecular recognition of single-walled carbon nanotubes. ---
1258  2020 Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. DIC, ED, ICUs
1259  2020 Aging-Related Increase of cGMP Disrupts Mitochondrial Homeostasis in Leydig Cells. ---
1260  2020 Alterations in the phosphodiesterase type 5 pathway and oxidative stress correlate with erectile function in spontaneously hypertensive rats. alpha1-AR, CCSM, ED, ES, NOS, SHR, WKY
1261  2020 An MRTF-A-Sp1-PDE5 Axis Mediates Angiotensin-II-Induced Cardiomyocyte Hypertrophy. Ang II, MRTF-A, Sp1
1262  2020 Assessment of preclinical effect of (+)-catechin hydrate on sexual function: An in silico and in vivo study. ---
1263  2020 Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder. BPH/LUTS, NOS, OAB, PBOO, SNP
1264  2020 Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide. I/R, LV, MetS, NO
1265  2020 Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection? COVID-19
1266  2020 Design and synthesis of pyrazolo[3,4-d]pyrimidinone derivatives: Discovery of selective phosphodiesterase-5 inhibitors. ---
1267  2020 Design, synthesis and biological evaluation of new 2-aminothiazole scaffolds as phosphodiesterase type 5 regulators and COX-1/COX-2 inhibitors. ---
1268  2020 Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. AD, CREB, NO
1269  2020 Direct-To-Consumer Internet Prescription Platforms Overlook Crucial Pathology Found During Traditional Office Evaluation of Young Men With Erectile Dysfunction. DTC, ED
1270  2020 Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket. EVO
1271  2020 Discovery of Novel Agents on Spindle Assembly Checkpoint to Sensitize Vinorelbine-Induced Mitotic Cell Death Against Human Non-Small Cell Lung Cancers. Bcl-2, BUBR1, NSCLC
1272  2020 Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors. COX-2
1273  2020 Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. cGMP, CLD, HDACs, HSC, PKG, TGF-beta
1274  2020 Effect of daily tadalafil on reported outcomes in patients with erectile dysfunction and depressive symptoms: STROBE, a case-control study. ED, IIEF, LUTS, SDS
1275  2020 Effects of "metabolic memory" on erectile function in diabetic men: A retrospective case-control study. DM, ED, EHS, IIEF, SEP
1276  2020 Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review. AMD, CSC, RPE
1277  2020 Efficacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart disease: the SV-INHIBITION study design. SV
1278  2020 Efficacy of vardenafil in human nasal mucosa. ---
1279  2020 Epidemiology and Treatment Barriers of Patients With Erectile Dysfunction Using an Online Prescription Platform: A Cross-Sectional Study. ED, OPPs
1280  2020 Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model. ERA, ET-1, NE, PA, PAH
1281  2020 Extracts from Almond (Terminalia catappa) leaf and stem bark mitigate the activities of crucial enzymes and oxidative stress associated with hypertension in cyclosporine A-stressed rats. ACE, AChE, ADA, CsA, SOD, TBARS
1282  2020 Fluorescence polarisation for high-throughput screening of adulterated food products via phosphodiesterase 5 inhibition assay. ICP, LC-HRMS
1283  2020 Formulation and Optimization of Avanafil Biodegradable Polymeric Nanoparticles: A Single-Dose Clinical Pharmacokinetic Evaluation. AVA, NPs, PVA, SE
1284  2020 Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment. MAF, PAH
1285  2020 Higher expression of phosphodiesterase type 5 in the anterior fibromuscular stroma of the human prostate. AFMS, PZ, TZ gland
1286  2020 Icariside II, a PDE5 Inhibitor, Suppresses Oxygen-Glucose Deprivation/Reperfusion-Induced Primary Hippocampal Neuronal Death Through Activating the PKG/CREB/BDNF/TrkB Signaling Pathway. BDNF, cGMP, CREB, I/R, ICS II, LDH, OGD/R, PKG, TrkB
1287  2020 Identification of New Targets and the Virtual Screening of Lignans against Alzheimer's Disease. AD, ADMET, COX-2, iNOS, JNK-3, NOX1, NQO1, Nrf2, PTP1B
1288  2020 Iridoids and Amino Acid Derivatives from the Paraguayan Crude Drug Adenocalymma marginatum (ysypo hu). CCC
1289  2020 Isolation and identification of an isomeric sildenafil analogue as an adulterant in an instant coffee premix. ICP, LC-UV, NMR
1290  2020 Mechanisms underlying priapism in sickle cell disease: targeting and key innovations on the preclinical landscape. SCD
1291  2020 Medicinal plants as a potential source of Phosphodiesterase-5 inhibitors: A review. ED
1292  2020 Metabolomic profiling of liver tissues after acute administration of vardenafil in rats. ED
1293  2020 Moderate treadmill exercise improves spatial learning and memory deficits possibly via changing PDE-5, IL-1 beta and pCREB expression. IL-1beta, MWM
1294  2020 No association between use of phosphodiesterase 5 inhibitors and colorectal cancer in men with erectile dysfunction. CRC
1295  2020 PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: Repurposing Sildenafil for the treatment of hypertensive cardiac hypertrophy. SHR, SIL
1296  2020 PDE5 inhibitor sildenafil attenuates cardiac microRNA 214 upregulation and pro-apoptotic signaling after chronic alcohol ingestion in mice. miR-214
1297  2020 Pharmacology and perspectives in erectile dysfunction in man. ED
1298  2020 Phosphodiesterase 5 (PDE5) restricts intracellular cGMP accumulation during enterotoxigenic Escherichia coli infection. ETEC, HEM, ST
1299  2020 Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. NO, PDEs
1300  2020 Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. Cpc-PH, HFpEF, PASP, PH
1301  2020 Phosphodiesterase 5 Inhibitor Use and Risk of Conventional and Serrated Precursors of Colorectal Cancer. CI
1302  2020 Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome. CP/CPPS, CPSI, NSAIDs, SD
1303  2020 Phosphodiesterase Type 5 Inhibitors Synergize Vincristine in Killing Castration-Resistant Prostate Cancer Through Amplifying Mitotic Arrest Signaling. CRPC, SAC
1304  2020 Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer. CRC
1305  2020 Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. NO-cGMP, PH, sGC
1306  2020 Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range. ---
1307  2020 Repurposing of the PDE5 Inhibitor Sildenafil for the Treatment of Persistent Pulmonary Hypertension in Neonates. cGMP, NO, PAH, PDE5is, PPHN
1308  2020 Restoration of Cavernous Veno-Occlusive Function through Chronic Administration of a Jun-Amino Terminal Kinase Inhibitor and a LIM-Kinase 2 Inhibitor by Suppressing Cavernous Apoptosis and Fibrosis in a Rat Model of Cavernous Nerve Injury: A Comparison with a Phosphodiesterase Type 5 Inhibitor. JNK, LIMK2, SM
1309  2020 Role of soluble guanylyl cyclase in renal afferent and efferent arterioles. AA, EA, NO, sGC
1310  2020 Shift Work Sleep Disorder and Night Shift Work Significantly Impair Erectile Function. ED, IIEF, PHQ-9, SWSD
1311  2020 Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor? ---
1312  2020 Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. BPD, ED, PAH, PDE, PE
1313  2020 Sildenafil for the Treatment of Alzheimer's Disease: A Systematic Review. AD, cAMP, cGMP, PDE2, PGC-1alpha
1314  2020 Sildenafil in Combination Therapy against Cancer: A Literature Review. NO
1315  2020 Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling. cKO, GEM
1316  2020 Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2. ---
1317  2020 Sildenafil-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: Case report with review. ---
1318  2020 Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. ERAs, PAH, TDM
1319  2020 Sonography of the penis/erectile dysfunction. ED, US
1320  2020 Species differences in the CYP3A-catalyzed metabolism of TPN729, a novel PDE5 inhibitor. ---
1321  2020 Structure elucidation of a PDE5 inhibitor detected as an illegal adulteration in a libido-boosting dietary supplement. LC-DAD, LC-MS, NMR
1322  2020 Structure of Human Phosphodiesterase 5A1 Complexed with Avanafil Reveals Molecular Basis of Isoform Selectivity and Guidelines for Targeting alpha-Helix Backbone Oxygen by Halogen Bonding. ---
1323  2020 Suspected-target and non-targeted screenings of phosphodiesterase 5 inhibitors in herbal remedies using liquid chromatography-quadrupole time-of-flight-mass spectrometry. LC-QTOF-MS
1324  2020 Swimming exercise inhibits myocardial ER stress in the hearts of aged mice by enhancing cGMP‑PKG signaling. ER, ROS
1325  2020 Tadalafil alleviates cisplatin-induced reproductive toxicity through the activation of the Nrf2/HO-1 pathway and the inhibition of oxidative stress and apoptosis in male rats. CIS, TDF, ZnPP
1326  2020 Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome. IBS
1327  2020 Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. NO
1328  2020 Testosterone positively regulates functional responses and nitric oxide expression in the isolated human corpus cavernosum. cGMP, ED, eNOS, HCC, NO, PHE
1329  2020 The Association Between Phosphodiesterase-5 Inhibitors and Colorectal Cancer in a National Cohort of Patients. CI, HR, VA
1330  2020 The hypertensive effect of sorafenib is abolished by sildenafil. NO, TKI
1331  2020 Vardenafil increases intracellular accumulation of the most prevalent mutant cystic fibrosis transmembrane conductance regulator (CTFR) in human bronchial epithelial cells. CF, CFTR, CTFR, PKG
1332  2020 [Identification of Descarbonsildenafil in an Adulterated Dietary Supplement and Evaluation of Its Inhibitory Activity for Phosphodiesterase Type 5 (PDE5)]. LC-QTOF-MS
1333  2020 [PDE5 inhibitors as a medicinal guide drug in the treatment of erectile dysfunction]. TCM
1334  2021 A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects. PAH
1335  2021 Antinociceptive Effect of Lodenafil Carbonate in Rodent Models of Inflammatory Pain and Spinal Nerve Ligation-Induced Neuropathic Pain. cGMP, L-NAME, NO
1336  2021 Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. AEs, ED, IIEF, PRISMA, WMD
1337  2021 Beneficial Effects of Human Umbilical Cord Blood Mononuclear Cells on Persistent Erectile Dysfunction After Treatment of 5-Alpha Reductase Inhibitor in Rats. 5ARI, CC, EFS, eNOS, HIF, HUCB, MNCs, nNOS
1338  2021 Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men. BTX-A, CI, MIRA, OAB, PRISMA, RCTs
1339  2021 Bilateral Sequential Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). HVF, NAION
1340  2021 Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. ---
1341  2021 Cerebrovascular Reactivity Measures Are Associated With Post-traumatic Headache Severity in Chronic TBI; A Retrospective Analysis. CVR, fMRI, HIT-6, PPTH, TBI, TCVI
1342  2021 Combined Effects of Oligopeptides Isolated from Panax ginseng C.A. Meyer and Ostrea gigas Thunberg on Sexual Function in Male Mice. cGMP, NO
1343  2021 Compliance with Testosterone Replacement Therapy in Patients with Testosterone Deficiency Syndrome: A 10-Year Observational Study in Korea. TDS, TRT
1344  2021 Cyclic GMP in Liver Cirrhosis-Role in Pathophysiology of Portal Hypertension and Therapeutic Implications. cGMP, eNOS, PH, sGC
1345  2021 Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors. ANP, BP, cGMP, MNC, T2D
1346  2021 Diets supplemented with raw and roasted pumpkin (Cucurbita pepo L) seeds improved some biochemical parameters associated with erectile function in rats. AChE, ADA, MDA
1347  2021 Diketopiperazine-Based, Flexible Tadalafil Analogues: Synthesis, Crystal Structures and Biological Activity Profile. ---
1348  2021 Eco-friendly stability-indicating RP-HPTLC method for sildenafil analysis, characterization and biological evaluation of its oxidized stress degradation product. EP, ICH, PEI, RP-HPTLC, SDL N-oxide, SLD
1349  2021 Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study. ---
1350  2021 Efficacy Evaluation of Plant Products in the Treatment of Erectile Dysfunction Related to Diabetes. STZ
1351  2021 Endothelin receptor antagonists for pulmonary arterial hypertension. CENTRAL, CI, ERAs, NYHA, OR, WHO
1352  2021 Exosomal miRNAs as Potential Biomarkers to Monitor Phosphodiesterase 5 Inhibitor Induced Anti-Fibrotic Effects on CCl4 Treated Rats. miRNAs
1353  2021 First molecular modelling report on tri-substituted pyrazolines as phosphodiesterase 5 (PDE5) inhibitors through classical and machine learning based multi-QSAR analysis. cGMP
1354  2021 Functional nitrergic innervation of smooth muscle structures in the mucosa of pig lower urinary tract. CGRP, EFS, MM, nNOS, NO, SMC-LP, TH
1355  2021 Health benefits and phenolic compounds of Moringa oleifera leaves: A comprehensive review. ACE, KIM-1, MO
1356  2021 Impacts of caffeine on resistant chicken's performance and cardiovascular gene expression. ADORA1, BW, PH, SERT
1357  2021 Inhibition of Phosphodiesterase 5 Promotes the Aromatase-Mediated Estrogen Biosynthesis in Osteoblastic Cells by Activation of cGMP/PKG/SHP2 Pathway. cGMP, PKG
1358  2021 Is Tadalafil an Effective Treatment Option for Interstitial Cystitis/Painful Bladder Syndrome? A Report of a Challenging Case. cGMP, CPP, IC/PBS, NO
1359  2021 Lead and mercury 28day exposure at small concentrations reduces smooth muscle relaxation by decreasing cGMP. ---
1360  2021 New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. cGMP
1361  2021 Novel synthesized attapulgite nanoparticles-based hydrophobic monolithic column for in-tube solid-phase microextraction of thiosildenafil, pseudovardenafil, and norneosildenafil in functional foods. ATP, EDMA, SPME, VBIMBr
1362  2021 On the Viability of Tadalafil-Based 18F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging. cGMP, NO, PET
1363  2021 Osthole alleviates pulmonary vascular remodeling by modulating microRNA-22-3p mediated lipid metabolic reprogramming. cGMP, CPT1A, FAS, HDL-C, HK2, IDH3alpha, IR, ND1, PAH, PLA2, TC, TG
1364  2021 Over-expression of PDE5 in Oral Squamous Cell Carcinoma - Effect of Sildenafil Citrate. OSCC, SC
1365  2021 Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie's Disease. ED, PD
1366  2021 PDE-5 inhibitors in selected herbal supplements from the Ghanaian market for better erectile function as tested by a bioassay. ED, HTS
1367  2021 Recent applications of phosphodiesterase (PDE5) inhibition assays for detecting adulterated sexual enhancement products. ED
1368  2021 Relaxation effects of Eriobotrya japonica toward tracheal smooth muscle via action mechanism on histamine-1 receptor and phosphodiesterase-5 enzyme. ---
1369  2021 Retrospective Observational Real-World Outcome Study to Evaluate Safety Among Patients With Erectile Dysfunction (ED) With Co-Possession of Tadalafil and Anti-Hypertensive Medications (anti-HTN). anti-HTN, CI, ED, IRRs
1370  2021 Significant Increase of Erectile Dysfunction in Men With Post-stroke: A Comprehensive Review. CI, ED, IIEF-5, RR, SMD
1371  2021 Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era. ---
1372  2021 Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications. HDAC, NK
1373  2021 Sildenafil-Mediated Neuroprotection from Adult to Neonatal Brain Injury: Evidence, Mechanisms, and Future Translation. ---
1374  2021 Structural Determination, Biological Function, and Molecular Modelling Studies of Sulfoaildenafil Adulterated in Herbal Dietary Supplement. ---
1375  2021 Tadalafil Reversed H-89 - and Scopolamine - Induced Spatial Learning Impairments in Male Rats. AD, MWM
1376  2021 Tadalafil Reverses the Effect of Three-Dimensional Cell Culture System on Stem Cell Features in A549 and SK-MES-1. CCK, CSC, EMT, qPCR
1377  2021 Tadalafil treatment improves cardiac, renal and lower urinary tract dysfunctions in rats with heart failure. DM, EFS, HF, LUTS, LV
1378  2021 The effect of pharmacotherapy on prostate volume, prostate perfusion and prostate-specific antigen (prostate morphometric parameters) in patients with lower urinary tract symptoms and benign prostatic obstruction. A systematic review and meta-analysis. 5ARI, PRISMA, PSA, RCTs, SMD, TPV, TZV
1379  2021 The effect of phosphodiesterase-5 inhibitors on uteroplacental and fetal cerebral perfusion in pregnancies with fetal growth restriction: A systematic review and meta-analysis. CIs, FGR, WMDs
1380  2021 The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews. CI, ED, WMD
1381  2021 The PDE5 inhibitor udenafil ameliorates nonalcoholic fatty liver disease by improving mitochondrial function. NAFLD, TG
1382  2021 The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. ABC, ED, EPR, ROS
1383  2021 Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia. ---
1384  2021 Visual Side Effects Linked to Sildenafil Consumption: An Update. cGMP, CTs, ED, ERG, IOP, NAION
1385  2022 A Comprehensive Review of the Pharmacologic Perspective on Loop Diuretic Drug Interactions with Therapeutically Used Drugs. ACE inhibitors, DOAJ, NSAIDs
1386  2022 Absorption, distribution, metabolism, and excretion of [14C]TPN729 after oral administration to rats. ED
1387  2022 Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease : A Case-Crossover Study. ICD-10, IHD, OR
1388  2022 Ameliorative Sexual Behavior and Phosphodiesterase-5 Inhibitory Effects of Spondias mangifera Fruit Extract in Rodents: In Silico, In Vitro, and In Vivo Study. SMFE
1389  2022 An update on the management algorithms of priapism during the last decade. IP, NIP, SP
1390  2022 Aphrodisiac Performance of Bioactive Compounds from Mimosa pudica Linn.: In Silico Molecular Docking and Dynamics Simulation Approach. ED, MD
1391  2022 Blockading a new NSCLC immunosuppressive target by pluripotent autologous tumor vaccines magnifies sequential immunotherapy. ATVs, CTLs, iNOS, PD-L1, TCM
1392  2022 Combination therapy of doxorubicin and Sildenafil inhibits the growth of pediatric rhabdomyosarcoma. ROS
1393  2022 Deciphering the myth of icariin and synthetic derivatives in improving erectile function from a molecular biology perspective: a narrative review. EH, ESCs, ICA II
1394  2022 Diet, herbs and erectile function: A good friendship! ACE, AChE, ADA
1395  2022 Effect of Antioxidants Supplementation on Erectile Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. CIs, ED, IIEF, SMDs
1396  2022 Effect of Flavonoid-Rich Extract From Dalbergiella welwitschii Leaf on Redox, Cholinergic, Monoaminergic, and Purinergic Dysfunction in Oxidative Testicular Injury: Ex Vivo and In Silico Studies. ACE, COX-2, FEDW, MAO, MDA, NO
1397  2022 Effect of Maternal Sildenafil Supplementation During Gestation on the Reproductive Performance of Sows/Gilts and Growth Performance of Neonatal Piglets. GD
1398  2022 Effects of phosphodiesterase 5 inhibition on cardiovascular function in resistant hypertension: A systematic review. BP, RH
1399  2022 Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial. HFrEF, IQR, PASP, PHT, SilHF
1400  2022 Effects of Tadalafil on skeletal muscle tissue: exploring interactions and novel mechanisms of action. ---
1401  2022 Efficacy of Adjusted Dose Tadalafil for Treating Erectile Dysfunction in Patients on Chronic Hemodialysis. IIEF
1402  2022 Evaluating the efficacy of intraplaque injection of dexamethasone with oral tadalafil in the chordee patients with Peyronie disease. PD
1403  2022 Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats. ED, eNOS, GJG, ICP, MAP, NADPH, nNOS
1404  2022 How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme. cGMP, CNS, GBM, TME
1405  2022 In vitro inhibition of phosphodiesterase type 4 enhances rat corpus cavernosum nerve-mediated relaxation induced by gasotransmitters. cAMP, CC, cGMP, EFS, NO
1406  2022 Mirodenafil ameliorates skin fibrosis in bleomycin-induced mouse model of systemic sclerosis. BLM, SSc, TGF
1407  2022 Modulation of SIRT1 expression improves erectile function in aged rats. cGMP, dUTP, FOXO3a, ICP, MAP, MDA, NAM, NO, SIRT1, SOD, TdT
1408  2022 Nitric Oxide Signalling in Descending Vasa Recta after Hypoxia/Re-Oxygenation. AKI, DVR, sGC
1409  2022 Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension. CYP3A4, ED, FDA, PAH, UGT1A9
1410  2022 Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions. AD, cGMP, CREB, DKK1, GR, GSK-3beta
1411  2022 Phosphodiesterase 5 inhibitor sildenafil potentiates the antitumor activity of cisplatin by ROS-mediated apoptosis: a role of deregulated glucose metabolism. cyt c, GLUT1, HIF-1alpha, HKII, LDHA, OXPHOS, PDK1, PKM2, ROS
1412  2022 Phosphodiesterase-5 Inhibitory Activity of Canthin-6-One Alkaloids and the Roots of Eurycoma longifolia and Eurycoma harmandiana. EH, EL
1413  2022 Plantain peels restore sexual performance, hormonal imbalance, and modulate nitric oxide production and key enzymes of penile function in paroxetine-sexually impaired male rats. ACE, AChE, ADA, ED, FSH, LH, PAR, TBARS
1414  2022 ROCK and PDE-5 Inhibitors for the Treatment of Dementia: Literature Review and Meta-Analysis. ROCK
1415  2022 Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. T2DM
1416  2022 Sildenafil (Viagra) Aggravates the Development of Experimental Abdominal Aortic Aneurysm. AAA, SMC
1417  2022 Tadalafil and Steroid Hormones Interactions in Adipose, Bone and Prostate Tissues: Focus on Translational Perspectives. AR, BPH, Cyp19a1, ED, ERbeta
1418  2022 The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders. cGMP, GC, NO, P2Y12, PDE5i, PDEs